var title_f17_7_17520="Evaluation of patients with mild TBI";
var content_f17_7_17520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute evaluation and disposition of patients with mild TBI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 594px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Vos, PE. Eur J Neurol 2002; 9:207 and Borg, J. J Rehabil Med 2004; S43:61.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17520=[""].join("\n");
var outline_f17_7_17520=null;
var title_f17_7_17521="Patient information: Kyphosis in children (The Basics)";
var content_f17_7_17521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83676\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/4/43072\">",
"         Kyphosis in a child",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Kyphosis in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/kyphosis-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H110678342\">",
"      <span class=\"h1\">",
"       What is kyphosis in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Kyphosis is the term doctors use for a curving of the upper back. A normal backbone, also called the &ldquo;spine,&rdquo; has a slight curve. In a child with kyphosis, the upper part of the spine curves more than normal, causing a rounded or hunched back (",
"      <a class=\"graphic graphic_figure graphicRef83509 \" href=\"UTD.htm?42/4/43072\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H110678357\">",
"      <span class=\"h1\">",
"       What causes kyphosis in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Kyphosis in children is caused by problems with the vertebrae. Vertebrae are the bones of the spine that sit on top of one another like a stack of coins. The main types of kyphosis include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Congenital kyphosis &ndash; In this condition, a baby is born with kyphosis. This happens because of a problem with the vertebrae that happens before birth. &ldquo;Congenital&rdquo; means a condition a person is born with.",
"       </li>",
"       <li>",
"        Postural kyphosis &ndash; This problem happens if a child does not stand up straight or slouches. It is more common in teenage girls than in younger girls or boys of any age. &nbsp;",
"       </li>",
"       <li>",
"        Scheuermann kyphosis &ndash; In this condition, some vertebrae in the upper spine are shaped like a wedge instead of a rectangle. This causes the upper part of the spine to curve. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H110678374\">",
"      <span class=\"h1\">",
"       What are the symptoms of kyphosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is a hunched or rounded back that might hurt or feel stiff.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H110678389\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. The doctor or nurse should be able to tell if your child has kyphosis by doing an exam. But he or she might order a back X-ray and other tests. These tests will allow the doctor or nurse to see the bones of the spine and measure the curve of the back.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H110678404\">",
"      <span class=\"h1\">",
"       How is kyphosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on what caused the problem and how serious it is.",
"     </p>",
"     <p>",
"      Children with congenital kyphosis often need surgery to fix the vertebrae problems.",
"     </p>",
"     <p>",
"      Children with postural kyphosis often do not need treatment. Exercises to stretch and strengthen the back can help, but children often do not do the exercises as directed.",
"     </p>",
"     <p>",
"      Children with Scheuermann kyphosis can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Do exercises to stretch and strengthen the back",
"       </li>",
"       <li>",
"        Avoid activities that cause pain",
"       </li>",
"       <li>",
"        Take medicines to ease pain",
"       </li>",
"       <li>",
"        Wear a back brace",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If they continue to have pain or have severe kyphosis, children with Scheuermann kyphosis sometimes need surgery.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?17/7/17521?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83676 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-0B08567BAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17521=[""].join("\n");
var outline_f17_7_17521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110678342\">",
"      What is kyphosis in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110678357\">",
"      What causes kyphosis in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110678374\">",
"      What are the symptoms of kyphosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110678389\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110678404\">",
"      How is kyphosis treated?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83676\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/4/43072\">",
"      Kyphosis in a child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_7_17522="Vaccination during pregnancy";
var content_f17_7_17522=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Vaccination during pregnancy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/7/17522/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17522/contributors\" id=\"au4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/7/17522/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17522/contributors\" id=\"se4723\">",
"       Charles J Lockwood, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17522/contributors\" id=\"se6247\">",
"       Peter F Weller, MD, FACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/7/17522/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17522/contributors\" id=\"de8449\">",
"       Allyson Bloom, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?17/7/17522?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Vaccines work by stimulating the immune system to produce antibodies, which can fight infections and prevent you from becoming ill. Some immunizations are safe to give during pregnancy, while others should be given at least one month before becoming pregnant. Certain immunizations may be recommended for women who are at high risk of becoming infected during pregnancy, but are not recommended for pregnant women at low risk of infection.",
"    </p>",
"    <p>",
"     Immunizations for nonpregnant adults are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"      \"Patient information: Adult vaccines (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WOMEN PLANNING PREGNANCY",
"     </span>",
"    </p>",
"    <p>",
"     Women planning pregnancy should have received all routine vaccinations as recommended by the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"      \"Patient information: Adult vaccines (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"      \"Standard immunizations for children and adolescents\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The measles, mumps, rubella, and chickenpox (varicella) vaccines are particularly important for women of childbearing age who are susceptible to these infections and who may become pregnant because these vaccines are contraindicated during pregnancy, and infection occurring in nonimmune pregnant women can adversely affect pregnancy outcome. Most American women of childbearing age are immune to these infections because of routine vaccinations given during childhood. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"      \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1148297418\">",
"     <span class=\"h2\">",
"      Measles, mumps, rubella (MMR)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Your healthcare provider can determine if you are immune to these infections by performing a blood test. If you are not immune, you should have the MMR vaccine at least 28 days before becoming pregnant. Contracting a measles, mumps, or rubella (German measles) infection in early pregnancy can cause miscarriage. Rubella infection in early pregnancy can also cause severe birth defects, including deafness and defects involving the eyes, heart,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     brain. Maternal infection in the second half of pregnancy is unlikely to cause these problems.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Varicella (chickenpox)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Becoming infected with chickenpox (varicella) during pregnancy, especially early pregnancy, increases the risk of birth defects. Chickenpox anytime in pregnancy can cause serious complications for the pregnant woman, such as pneumonia.",
"    </p>",
"    <p>",
"     If you have never had chickenpox or the varicella vaccine, your healthcare provider can determine if you are immune by performing a blood test. If you are not immune, you should have the varicella vaccine at least one month before becoming pregnant.",
"    </p>",
"    <p>",
"     If you are not immune to varicella and are exposed to someone with chickenpox or shingles while pregnant, contact your healthcare provider as soon as possible. There is a treatment called varicella zoster immune globulin (VariZIG) that can help to reduce the risk of becoming infected with chickenpox. VariZIG can be given within 10 days of exposure, but should be given as soon as possible. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link\">",
"      \"Varicella-zoster virus infection in pregnancy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Human papillomavirus",
"     </span>",
"     &nbsp;&mdash;&nbsp;The human papillomavirus (HPV) vaccine is recommended for nonpregnant girls and women 9 to 26 years of age. It is",
"     <strong>",
"      not",
"     </strong>",
"     recommended for pregnant women because its safety in pregnancy has not been studied.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Influenza (flu)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pregnant women are at especially high risk of developing complications of the flu. Vaccination against the seasonal flu is recommended for",
"     <strong>",
"      all",
"     </strong>",
"     women who are or will be pregnant during influenza season. There does not appear to be an increased risk of miscarriage with the influenza vaccine. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=see_link\">",
"      \"Patient information: Influenza prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Tetanus, diphtheria, and pertussis",
"     </span>",
"     &nbsp;&mdash;&nbsp;The tetanus, diphtheria, acellular pertussis (Tdap) vaccine is recommended for pregnant women, and should be given to women over 20 weeks of gestation to help protect the newborn from pertussis infection. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"      \"Immunizations during pregnancy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      VACCINES FOR HIGH RISK GROUPS",
"     </span>",
"    </p>",
"    <p>",
"     Some pregnant women, who are at high risk of certain infections due to travel or other circumstances, should consider additional vaccines.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Hepatitis A",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hepatitis A is a virus that can cause severe illness in pregnant women and can be passed to the fetus. The hepatitis A vaccine is probably safe to give during pregnancy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/61/22483?source=see_link\">",
"      \"Patient information: Hepatitis A (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The hepatitis A vaccine is recommended for pregnant women who are at risk for developing the illness.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Hepatitis B",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hepatitis B is a serious infection that causes inflammation of the liver. A series of three hepatitis B vaccines is now routinely given during childhood, although many adults have not been vaccinated. The vaccine carries no known risks to the developing fetus.",
"    </p>",
"    <p>",
"     The hepatitis B vaccine is recommended for pregnant women who are at high risk for acquiring hepatitis B during pregnancy, and also for women who started the immunization series before becoming pregnant. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"      \"Patient information: Hepatitis B (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Poliomyelitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Poliomyelitis (polio) is caused by a virus that can lead to permanent paralysis. Polio has been eliminated from the Americas and most other developed countries, but a number of other countries are still affected by large polio outbreaks. Pregnant women should avoid travel, if possible, to areas where polio is present. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"      \"Patient information: General travel advice (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A vaccine is available to prevent polio. However, polio vaccination is not usually recommended during pregnancy due to a lack of information about the vaccine's safety. If travel to an area where polio is prevalent is not avoidable, you should be immunized with the inactivated polio vaccine (IPV). (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=see_link\">",
"      \"Poliovirus vaccination\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Pneumococcus",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pneumococci are bacteria that are the leading cause of pneumonia and a number of other infections, including otitis media (ear infection) and meningitis. Women at high risk for pneumococcal infections should be given the pneumococcal vaccine.",
"    </p>",
"    <p>",
"     Ideally, the vaccine should be given before pregnancy. However, the pneumococcus vaccine appears to be safe when given in the second and third trimesters (there is not enough information about the safety of the vaccine during the first trimester). (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"      \"Immunizations during pregnancy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Yellow fever",
"     </span>",
"     &nbsp;&mdash;&nbsp;Yellow fever is a viral disease transmitted by mosquitoes. It is associated with liver and kidney damage and hemorrhage, and often leads to death. The disease occurs in tropical regions of South America and sub-Saharan Africa; these areas should be avoided during pregnancy, if possible.",
"    </p>",
"    <p>",
"     If travel is not avoidable and the risk of yellow fever is high, immunization with a live virus vaccine may be considered. You should consult an infectious disease specialist if yellow fever vaccination is needed. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"      \"Immunizations during pregnancy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Other immunizations",
"     </span>",
"     &nbsp;&mdash;&nbsp;Vaccines against a number of other infections are available, including cholera, meningococcus, plague, rabies, Japanese encephalitis, typhoid, smallpox, and Haemophilus influenzae B. A healthcare provider can determine the risk of exposure to these illnesses and the need for immunization during pregnancy. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"      \"Immunizations during pregnancy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H151\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10150162\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/52/8003?source=see_link\">",
"      Patient information: Vaccines and pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/39/33395?source=see_link\">",
"      Patient information: Avoiding infections in pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=see_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=see_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/42/42657?source=see_link\">",
"      Patient information: Group B streptococcal disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/10/14499?source=see_link\">",
"      Patient information: Rubella (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10150195\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/52/43843?source=see_link\">",
"      Patient information: Avoiding infections in pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=see_link\">",
"      Patient information: Influenza prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/61/22483?source=see_link\">",
"      Patient information: Hepatitis A (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=see_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"      Immunizations during pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6087?source=see_link\">",
"      Rubella in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=see_link\">",
"      Poliovirus vaccination",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/infectionsandpregnancy.html\">",
"      www.nlm.nih.gov/medlineplus/infectionsandpregnancy.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/nip/publications/preg_guide.htm\">",
"      www.cdc.gov/nip/publications/preg_guide.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Network for Immunization Information",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.immunizationinfo.org/immunization_issues_detail.cfv?id=90\">",
"      www.immunizationinfo.org/immunization_issues_detail.cfv?id=90",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Infectious Diseases Society of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.idsociety.org\">",
"      www.idsociety.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?17/7/17522/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?17/7/17522?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17522/abstract/1\">",
"      Committee on Obstetric Practice. ACOG Committee Opinion No. 521: Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Obstet Gynecol 2012; 119:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17522/abstract/2\">",
"      American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG Committee Opinion No. 468: Influenza vaccination during pregnancy. Obstet Gynecol 2010; 116:1006.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Guidelines for vaccinating pregnant women. file://www.cdc.gov/vaccines/pubs/preg-guide.htm (Accessed on January 03, 2013).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f17_7_17522=[""].join("\n");
var outline_f17_7_17522=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WOMEN PLANNING PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           VACCINES FOR HIGH RISK GROUPS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f17_7_17523="Osteonecrosis of knee MRI";
var content_f17_7_17523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteonecrosis of the femoral condyle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 544px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance images in a young woman on prednisone for inflammatory bowel disease who developed knee pain due to osteonecrosis of the femoral condyle without collapse (marrow infarction).",
"    <br>",
"     <br>",
"      Top panel: Sagittal proton density MRI image of the knee shows a serpentine \"double-line sign\" (concentric high and low signal at the periphery) (arrow) that represents hypervascular granulation tissue and is pathognomonic of osteonecrosis.",
"      <br>",
"       <br>",
"        Bottom panel: Coronal inversion recovery image (a fat saturation MRI sequence) again demonstrates serpentine intramedullary pattern of decreased signal intensity.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Courtesy of Mark Robbins, MD.",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17523=[""].join("\n");
var outline_f17_7_17523=null;
var title_f17_7_17524="Clinical microbiology review: Respiratory tract infections";
var content_f17_7_17524=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical microbiology review: Respiratory tract infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/7/17524/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17524/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/7/17524/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17524/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/7/17524/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17524/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/7/17524/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 1997.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;This specimen was obtained from a 52 year-old female with fever and a pulmonary infiltrate. What does the Gram's stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef51269 \" href=\"UTD.htm?4/30/4578\">",
"     picture 1",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_figure graphicRef81766 \" href=\"UTD.htm?8/12/8386\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;This sputum specimen was obtained from a 65 year-old man with new onset of fever, rigors, pleuritic chest pain, and productive cough. What does the Gram's stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef57528 \" href=\"UTD.htm?18/48/19203\">",
"     picture 2",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef69327 graphicRef59890 \" href=\"UTD.htm?43/43/44725\">",
"     picture 3A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CASE 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;This sputum specimen was obtained from a 58 year-old man with pneumonia following a viral illness. What does the Gram's stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef82062 \" href=\"UTD.htm?36/29/37328\">",
"     picture 4",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef59289 \" href=\"UTD.htm?39/7/40048\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72075 \" href=\"UTD.htm?18/34/18991\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77734 \" href=\"UTD.htm?27/24/28046\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CASE 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;This sputum specimen was produced by a 45 year-old man with a forty-pack-year smoking history and new fever. What does the Gram's stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef81344 \" href=\"UTD.htm?20/57/21392\">",
"     picture 7",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef58744 graphicRef59330 graphicRef72828 \" href=\"UTD.htm?42/54/43878\">",
"     picture 8A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CASE 5",
"    </span>",
"    &nbsp;&mdash;&nbsp;This sputum specimen was obtained from a 63 year-old man with a history of heavy smoking. What does the Gram's stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef73562 \" href=\"UTD.htm?13/38/13935\">",
"     picture 9",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef53625 \" href=\"UTD.htm?15/51/16191\">",
"     picture 10",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CASE 6",
"    </span>",
"    &nbsp;&mdash;&nbsp;This viscous sputum specimen was obtained from a 40 year-old man with alcoholism, new onset fever, and a lobar pneumonia with a bulging fissure on chest x-ray. What does the Gram's stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef65288 \" href=\"UTD.htm?24/39/25201\">",
"     picture 11",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef71969 \" href=\"UTD.htm?26/45/27345\">",
"     picture 12",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CASE 7",
"    </span>",
"    &nbsp;&mdash;&nbsp;This sputum specimen was obtained from an 18 year-old man with the acute onset of pneumonia during training as a military recruit. What does the Gram's stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef51985 \" href=\"UTD.htm?30/63/31743\">",
"     picture 13",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef62782 graphicRef75468 \" href=\"UTD.htm?33/32/34309\">",
"     picture 14A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CASE 8",
"    </span>",
"    &nbsp;&mdash;&nbsp;This sputum specimen was suctioned from the endotracheal tube of a 74 year-old man hospitalized for 10 days in a coronary care unit post-cardiac arrest. What does the Gram's stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef57623 \" href=\"UTD.htm?22/53/23376\">",
"     picture 15",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef66300 graphicRef77055 graphicRef56963 \" href=\"UTD.htm?7/25/7573\">",
"     picture 16A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CASE 9",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 64 year-old Chinese man presented with several weeks of fever, night sweats, weight loss, and intermittent hemoptysis. What does the Gram's stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef67716 \" href=\"UTD.htm?19/22/19823\">",
"     picture 17",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef82509 graphicRef54384 graphicRef67234 \" href=\"UTD.htm?36/25/37272\">",
"     picture 18A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CASE 10",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 45 year-old woman was receiving chemotherapy and steroids for Hodgkin lymphoma, and presented with a subacute febrile illness, dyspnea, and a pulmonary infiltrate. What does the Gram's stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef62923 \" href=\"UTD.htm?20/15/20734\">",
"     picture 19",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef70618 graphicRef53808 graphicRef65539 \" href=\"UTD.htm?18/19/18742\">",
"     picture 20A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CASE 11",
"    </span>",
"    &nbsp;&mdash;&nbsp;This specimen was obtained from an oral abscess following dental manipulation. What does the Gram's stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef63629 \" href=\"UTD.htm?17/29/17887\">",
"     picture 21",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef75457 graphicRef50367 \" href=\"UTD.htm?25/54/26468\">",
"     picture 22A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CASE 12",
"    </span>",
"    &nbsp;&mdash;&nbsp;This sputum specimen was expectorated by a 25 year-old female who was neutropenic following aggressive chemotherapy for acute myeloid leukemia. What does the Gram's stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef77431 \" href=\"UTD.htm?14/4/14400\">",
"     picture 23",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef56469 graphicRef64064 graphicRef75864 graphicRef54937 graphicRef66696 \" href=\"UTD.htm?21/20/21834\">",
"     picture 24A-E",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CASE 13",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 37 year-old man from the midwestern United States presented with a fever, night sweats, weight loss, and a diffuse pneumonia. What does the lung biopsy specimen show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef78977 \" href=\"UTD.htm?1/33/1555\">",
"     picture 25",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef54745 graphicRef69585 graphicRef81839 \" href=\"UTD.htm?23/42/24233\">",
"     picture 26A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CASE 14",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 44 year-old woman presented with a nodular lung lesion a few months after travelling in southern California and Arizona. What does the lung biopsy show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef60484 \" href=\"UTD.htm?7/40/7809\">",
"     picture 27",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef73243 graphicRef82517 \" href=\"UTD.htm?32/28/33221\">",
"     picture 28A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CASE 15",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 65 year-old man presented with fever, pneumonia, and splenomegaly. What does the splenic aspirate show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef70474 \" href=\"UTD.htm?29/35/30271\">",
"     picture 29",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef81163 graphicRef59292 \" href=\"UTD.htm?1/4/1090\">",
"     picture 30A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CASE 16",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 22 year-old woman presented in diabetic ketoacidosis, with facial swelling, proptosis, and necrosis of the palate on the right. What does the sinus biopsy show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef73721 \" href=\"UTD.htm?14/10/14511\">",
"     picture 31",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef53937 graphicRef58489 graphicRef71272 \" href=\"UTD.htm?36/46/37607\">",
"     picture 32A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CASE 17",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 28 year-old man with HIV infection presented with several days of increasing dyspnea and low-grade fever. What does the lung biopsy show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef59343 \" href=\"UTD.htm?22/7/22644\">",
"     picture 33",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef67997 \" href=\"UTD.htm?25/29/26068\">",
"     picture 34",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81492 \" href=\"UTD.htm?8/25/8607\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CASE 18",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 62 year-old man presented with fever and pleuritic chest pain a few days after a seizure related to alcoholism. What does the pleural fluid Gram's stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef73577 \" href=\"UTD.htm?26/55/27519\">",
"     picture 35",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef61771 \" href=\"UTD.htm?28/22/29039\">",
"     picture 36",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CASE 19",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 65 year-old man presented with three days of fever, chills, cough, and dyspnea, and had bilateral infiltrates by chest x-ray, but was unable to produce any sputum. What does the lung biopsy show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef59274 \" href=\"UTD.htm?39/6/40033\">",
"     picture 37",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef56800 graphicRef68568 \" href=\"UTD.htm?24/51/25396\">",
"     picture 38A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82315 \" href=\"UTD.htm?32/15/33011\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74516 \" href=\"UTD.htm?11/15/11506\">",
"     picture 39",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1272 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17524=[""].join("\n");
var outline_f17_7_17524=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CASE 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CASE 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CASE 5",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CASE 6",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CASE 7",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CASE 8",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CASE 9",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CASE 10",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CASE 11",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CASE 12",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CASE 13",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CASE 14",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CASE 15",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CASE 16",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CASE 17",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CASE 18",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CASE 19",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1272\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1272|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/25/8607\" title=\"diagnostic image 1\">",
"      Silver stain lung 1B answer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1272|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/12/8386\" title=\"figure 1\">",
"      Gram stain sputum 1 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/34/18991\" title=\"figure 2\">",
"      Gram stain sputum 3B answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/15/33011\" title=\"figure 3\">",
"      Gram stain lung 1C answer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1272|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/30/4578\" title=\"picture 1\">",
"      Gram stain sputum 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/48/19203\" title=\"picture 2\">",
"      Gram stain sputum 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/60/21443\" title=\"picture 3A\">",
"      Gram stain sputum 2A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/33/34334\" title=\"picture 3B\">",
"      Alpha hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/29/37328\" title=\"picture 4\">",
"      Gram stain sputum 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/7/40048\" title=\"picture 5\">",
"      Gram stain sputum 3A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/24/28046\" title=\"picture 6\">",
"      Coagulase test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/57/21392\" title=\"picture 7\">",
"      Gram stain sputum 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/62/23520\" title=\"picture 8A\">",
"      Gram stain sputum 4A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/15/22783\" title=\"picture 8B\">",
"      Haemophilus chocolate agar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/20/12623\" title=\"picture 8C\">",
"      X and V factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/38/13935\" title=\"picture 9\">",
"      Gram stain sputum 5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/51/16191\" title=\"picture 10\">",
"      Gram stain sputum 5 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/39/25201\" title=\"picture 11\">",
"      Gram stain sputum 6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/45/27345\" title=\"picture 12\">",
"      Gram stain sputum 6 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/63/31743\" title=\"picture 13\">",
"      Gram stain sputum 7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/33/33311\" title=\"picture 14A\">",
"      Gram stain sputum 7A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/54/34657\" title=\"picture 14B\">",
"      Gram stain sputum 7B answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/53/23376\" title=\"picture 15\">",
"      Gram stain sputum 8",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/6/26735\" title=\"picture 16A\">",
"      Gram stain sputum 8A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/39/43646\" title=\"picture 16B\">",
"      Gram stain sputum 8B answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/7/32894\" title=\"picture 16C\">",
"      Gram stain sputum 8C answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/22/19823\" title=\"picture 17\">",
"      Gram stain sputum 9",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/26/21935\" title=\"picture 18A\">",
"      Gram stain sputum 9A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/10/39087\" title=\"picture 18B\">",
"      Gram stain sputum 9B answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/33/8724\" title=\"picture 18C\">",
"      Gram stain sputum 9C answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/15/20734\" title=\"picture 19\">",
"      Gram stain sputum 10",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/56/23438\" title=\"picture 20A\">",
"      Gram stain sputum 10A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/39/19071\" title=\"picture 20B\">",
"      Gram stain sputum 10B answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/61/31696\" title=\"picture 20C\">",
"      Gram stain sputum 10C answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/29/17887\" title=\"picture 21\">",
"      Gram stain abscess 11",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/32/21007\" title=\"picture 22A\">",
"      Gram stain abscess 11A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/22/34144\" title=\"picture 22B\">",
"      Gram stain abscess 11B answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/4/14400\" title=\"picture 23\">",
"      Gram stain sputum 12",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/20/16704\" title=\"picture 24A\">",
"      Gram stain sputum 12A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/18/5408\" title=\"picture 24B\">",
"      Gram stain sputum 12B answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/29/25043\" title=\"picture 24C\">",
"      Gram stain sputum 12C answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/24/24975\" title=\"picture 24D\">",
"      Gram stain sputum 12D answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/25/10655\" title=\"picture 24E\">",
"      Gram stain sputum 12E answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/33/1555\" title=\"picture 25\">",
"      Histology lung 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/39/3699\" title=\"picture 26A\">",
"      Histology lung 1A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/23/42352\" title=\"picture 26B\">",
"      Histology lung 1B answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/40/22145\" title=\"picture 26C\">",
"      Histology lung 1C answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/40/7809\" title=\"picture 27\">",
"      Histology lung 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/4/11329\" title=\"picture 28A\">",
"      Histology lung 2A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/54/5984\" title=\"picture 28B\">",
"      Histology lung 2B answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/35/30271\" title=\"picture 29\">",
"      Spleen aspirate 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/54/32623\" title=\"picture 30A\">",
"      Spleen aspirate 1A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/37/25182\" title=\"picture 30B\">",
"      Spleen aspirate 1B answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/10/14511\" title=\"picture 31\">",
"      Sinus biopsy 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/7/16511\" title=\"picture 32A\">",
"      Sinus biopsy 1A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/52/2882\" title=\"picture 32B\">",
"      Sinus biopsy 1B answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/10/29871\" title=\"picture 32C\">",
"      Sinus biopsy 1C answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/7/22644\" title=\"picture 33\">",
"      Silver stain lung 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/29/26068\" title=\"picture 34\">",
"      Silver stain lung 1A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/55/27519\" title=\"picture 35\">",
"      Gram stain pleural fluid 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/22/29039\" title=\"picture 36\">",
"      Gram stain pleural 1 answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/6/40033\" title=\"picture 37\">",
"      Gram stain lung biopsy 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/41/42641\" title=\"picture 38A\">",
"      Gram stain lung 1A answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/21/27998\" title=\"picture 38B\">",
"      Gram stain lung 1B answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/15/11506\" title=\"picture 39\">",
"      Selective media",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_7_17525="General principles of radiation therapy for head and neck cancer";
var content_f17_7_17525=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of radiation therapy for head and neck cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/7/17525/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17525/contributors\">",
"     Shiyu Song, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/7/17525/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17525/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17525/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17525/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/7/17525/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17525/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/7/17525/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) is an important treatment modality for head and neck cancer. For many sites, RT yields better functional outcomes than surgery and thus is often preferred for localized disease. For locoregionally advanced lesions, RT is often used either as adjuvant therapy after surgery or in combination with chemotherapy as definitive organ preserving treatment.",
"   </p>",
"   <p>",
"    The general principles of RT for head and neck squamous cell carcinoma will be reviewed here. The approach to dose and schedule for definitive radiation therapy of head and neck cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ionizing radiation produces its biologic effects by imparting energy to tissues, thereby causing DNA damage and loss of cellular reproductive ability. Some cells die relatively rapidly through apoptosis. However, most cells do not manifest evidence of damage until mitosis occurs, and several divisions may ensue before actual cell death (termed mitotic cell death). For this reason, most tumors do not show immediate shrinkage after starting RT and may take weeks or longer to shrink. Some low-grade, slowly proliferating tumors histologically appear to be viable for prolonged periods after irradiation.",
"   </p>",
"   <p>",
"    The unit of absorbed radiation dose is the gray (Gy), which is defined as the absorption of 1 joule of energy per kilogram of matter (water or human tissue). One Gy is equivalent to 100 centigray (cGy) or 100 rads (the formerly used unit of measure). The energy of radiation determines the depth of tissue penetration as well as the nature of the atomic interaction.",
"   </p>",
"   <p>",
"    Radiation can be administered by an external beam source or by brachytherapy using either interstitial implants or intracavitary techniques. The choice of technique depends upon the site of a tumor and the goal of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EXTERNAL BEAM RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most head and neck cancers are treated with external beam radiation therapy (RT). The most commonly used forms of ionizing radiation are high energy photons (ie, x-ray) and electrons, both of which are produced by linear accelerators. The choice of photons versus electrons and beam energy is based upon tumor location and target volume.",
"   </p>",
"   <p>",
"    Heavy charged particles, such as protons or carbon ions remain investigational, although proton beam facilities are becoming more widely available. Clinical trials comparing photon irradiation with proton beam are limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=see_link\">",
"     \"Proton and ion beams in cancer therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Linear accelerators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photons are usually generated by a linear accelerator, which uses high frequency electromagnetic waves to accelerate electrons to high energy. The electron beam strikes a target in the machine that produces the photon beam that is used to treat deep-seated tumors. Alternatively, the electron beam itself may be used to treat superficial tumors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Photons &ndash;",
"      <strong>",
"      </strong>",
"      Photons with energy in the megavoltage range exhibit important skin-sparing effects. With increasing energy, the maximum tissue dose occurs at a greater depth. In the head and neck region, photons with energies in the 4 to 6 megavolt (MeV) range typically are used. This is desirable when treating a deep lesion but not for a skin recurrence or superficial lymph nodes.",
"      <br/>",
"      <br/>",
"      To treat superficial lesions, a material with similar density to tissue (&ldquo;bolus&rdquo;) can be placed directly on the skin surface. The photon beam then strikes the absorbing surface, whose thickness is calculated so that the maximum dose to the target volume occurs closer to the skin surface.",
"     </li>",
"     <li>",
"      Electrons &ndash;",
"      <strong>",
"      </strong>",
"      Electrons with energies between 5 and 22 MeV are available on most linear accelerators. Electrons have some skin-sparing effects, but the maximum dose is reached more superficially and then falls off much more quickly than with photons. This characteristic may be exploited when there are critical structures deep to the target volume. As an example, electron beam therapy may be used to treat the posterior neck while sparing the spinal cord after maximum safe doses to the spinal cord have been given using photons.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493365036\">",
"    <span class=\"h2\">",
"     Imaging for treatment planning and setup",
"    </span>",
"    &nbsp;&mdash;&nbsp;Image-based determination of the location of the tumor and its relationship to normal structures is critical for RT planning. Advances in imaging technology have facilitated advances in RT treatment techniques.",
"   </p>",
"   <p>",
"    Advanced imaging technologies are required for three-dimensional conformal RT (3D-CRT) and intensity modulated radiotherapy (IMRT). A treatment planning scan, usually CT, is performed prior to therapy with the patient immobilized in the same position as will be employed for actual treatment. Ideally, IV contrast enhancement should be performed with a planning CT scan in order to optimally delineate the size and location of all tumor target volumes. The planning scan accurately determines the tumor volume as well as three-dimensional relationship of the tumor to normal anatomic structures in three dimensions. Other imaging techniques, including MRI and PET, may also have a role in delineating soft tissue and tumor anatomy.",
"   </p>",
"   <p>",
"    During actual treatment, patients are aligned for treatments by comparing bony structures on the CT scan with x-rays taken on a treatment linear accelerator. Megavoltage x-rays (portal films) are used to verify the patient's position and the position of the radiation fields. More recently, onboard kilovoltage x-ray imaging (or OBI) and cone-beam CT scanning capabilities have been incorporated into linear accelerators to enable more precise image-guided patient localization prior to each treatment. (See",
"    <a class=\"local\" href=\"#H1493365692\">",
"     'Image-guided RT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163948839\">",
"    <span class=\"h2\">",
"     Three-dimensional conformal RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current standard technique for delivery of RT to head and neck cancer is three-dimensional conformal radiation therapy (3D-CRT), which includes but is not restricted to intensity-modulated radiation therapy (IMRT). (See",
"    <a class=\"local\" href=\"#H1493365078\">",
"     'Intensity-modulated RT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Three-dimensional planning is based upon information that is obtained from CT scans, in contrast to older techniques that used two-dimensional planning based upon simulation X-ray films. With 3D-CRT, the anatomic relationship between the patient's tumor and normal anatomy is used to deliver a radiation dose that conforms to the target volume and minimizes exposure to other structures. Three-dimensional conformal RT requires a precise definition of anatomy, a sophisticated treatment planning system that can calculate the dose in three dimensions, and a treatment device that can deliver the specified dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493365078\">",
"    <span class=\"h3\">",
"     Intensity-modulated RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensity-modulated radiation therapy (IMRT) is an advanced form of 3D-CRT that is indicated for the treatment of most head and neck cancers excluding early stage vocal cord cancer and some salivary gland malignancies. IMRT uses non-uniform radiation beam intensities to maximize the delivery of radiation to the planned treatment volume while minimizing irradiation of normal tissue outside the target. IMRT is rapidly supplanting older treatment techniques for head and neck cancer despite theoretical concerns about the dose inhomogeneity, the additional time required for planning computation and QA verification, and the exposure of larger volumes of normal tissues to a lower dose [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17525/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=see_link\">",
"     \"Intensity-modulated radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies now demonstrate that IMRT can reduce side effects (particularly xerostomia), even in the setting of concurrent chemotherapy. The benefit of parotid sparing is showed in multiple studies, which showed salivary function preservation and better recovery of saliva output. The benefit of IMRT in preventing xerostomia was also demonstrated in the Parotid-sparing Intensity Modulated Versus Conventional Radiotherapy in Head and Neck Cancer (PARSPORT) trial [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17525/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link&amp;anchor=H722454159#H722454159\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Highly conformal RT technique'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493365692\">",
"    <span class=\"h3\">",
"     Image-guided RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily patient positioning errors that range from 3 mm to 10 mm can occur during RT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17525/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. To compensate for these errors, a safety margin of 5 to 10 mm of normal tissue is included in the treatment volume so that the tumor will not be \"missed\". The radiation administered to this normal tissue in the target volume can significantly increase toxicity.",
"   </p>",
"   <p>",
"    Image-guided radiation therapy (IGRT) utilizes high resolution on-board imaging to guide radiation delivery immediately prior to each radiation treatment, not just during the treatment planning process. These techniques include onboard orthovoltage x-ray imaging and cone-beam CT scanner. A further refinement of IGRT, namely image-guided adaptive radiation therapy (IGART), allows for adjustment of the radiation plan according to tumor size changes or normal organ shift during the course of the six to seven weeks of treatment. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493365739\">",
"    <span class=\"h3\">",
"     Treatment replanning and adaptive RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation treatments generally use a single treatment plan based on the initial size and location of the tumor and the normal organs. However, tumor size can change significantly during the course of radiation therapy, as can the size of the surrounding normal organs, because of weight loss and radiation damage to these organs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17525/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Thus, the relative locations of the tumor and normal organs may change during treatment; as a consequence, more normal tissue may be treated during the later course of the radiation treatment. Treatment replanning may be particularly important for patients receiving sequential chemoradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17525/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To mitigate this, adaptive replanning has been proposed. Replanning generates new plans at certain points when a significant change in tumor size occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17525/abstract/9\">",
"     9",
"    </a>",
"    ]. Although promising, routine replanning will markedly increase workload and require an increase in manpower. Replanning also requires an upgrade of the planning system in order to generate a new plan in a timely manner. To make replanning practical, a balance between the potential benefits of replanning and its costs are needed.",
"   </p>",
"   <p>",
"    When definitive RT is preceded by induction chemotherapy, appropriate imaging studies should be obtained prior to induction chemotherapy to serve as a reference for post-induction RT planning [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17525/abstract/8\">",
"     8",
"    </a>",
"    ]. Changes in body weight, neck contours, and tumor volumes that occur during the induction chemotherapy may necessitate replanning. However, the pretreatment primary tumor and gross nodal tumor volumes should be used for treatment planning even though tumor shrinkage may have occurred. All structures involved by tumor prior to induction chemotherapy should be included in the final treatment plan, even if gross tumor is no longer identifiable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BRACHYTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachytherapy places a radioactive source within or next to the tumor, using either an interstitial implant or an intracavitary device. For cancers in the head and neck region, temporary implants rather than permanent implants are used. Intracavitary brachytherapy places the radiation source in the lumen of cavitary structures, such as the nasopharynx or oral cavity. Brachytherapy can be used as a boost technique following external beam treatment or as the sole treatment in carefully selected small oral cavity or tonsillar tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17525/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although brachytherapy can deliver high doses of radiation to the target and spare surrounding tissues, it is an invasive procedure that has the potential to cause severe late side effects, especially osteoradionecrosis, and is not in widespread use for treatment of head and neck cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/35/24114?source=see_link\">",
"       \"Patient information: Brachytherapy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       \"Patient information: Radiation therapy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H841867\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most head and neck cancers are treated with external beam radiation therapy (RT) using high-energy photons generated by a linear accelerator. Image-based determination of the location of the tumor and its relationship to normal structures is critical for RT planning and accurate treatment delivery. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'External beam radiation therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the current standard technique for delivery of RT to head and neck cancer is still three-dimensional conformal radiation therapy (3D-CRT), intensity modulated RT (IMRT) and image-guided RT (IGRT) are becoming the dominant treatment techniques for the majority of the patients. Further refinements in technique have led to the development and implementation of adaptive radiation therapy, which may further improve the ability to deliver radiation to the tumor while sparing normal tissues and thus minimizing toxicity. (See",
"    <a class=\"local\" href=\"#H163948839\">",
"     'Three-dimensional conformal RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Dosing regimens and fractionation schedules are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17525/abstract/1\">",
"      Lee N, Puri DR, Blanco AI, Chao KS. Intensity-modulated radiation therapy in head and neck cancers: an update. Head Neck 2007; 29:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17525/abstract/2\">",
"      Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17525/abstract/3\">",
"      Pisani L, Lockman D, Jaffray D, et al. Setup error in radiotherapy: on-line correction using electronic kilovoltage and megavoltage radiographs. Int J Radiat Oncol Biol Phys 2000; 47:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17525/abstract/4\">",
"      Hong TS, Tom&eacute; WA, Chappell RJ, et al. The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005; 61:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17525/abstract/5\">",
"      Piermattei A, Cilla S, D'Onofrio G, et al. Large discrepancies between planned and actually delivered dose in IMRT of head and neck cancer. A case report. Tumori 2007; 93:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17525/abstract/6\">",
"      Hansen EK, Bucci MK, Quivey JM, et al. Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006; 64:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17525/abstract/7\">",
"      V&aacute;squez Osorio EM, Hoogeman MS, Al-Mamgani A, et al. Local anatomic changes in parotid and submandibular glands during radiotherapy for oropharynx cancer and correlation with dose, studied in detail with nonrigid registration. Int J Radiat Oncol Biol Phys 2008; 70:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17525/abstract/8\">",
"      Salama JK, Haddad RI, Kies MS, et al. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 75:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17525/abstract/9\">",
"      Mageras GS, Mechalakos J. Planning in the IGRT context: closing the loop. Semin Radiat Oncol 2007; 17:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17525/abstract/10\">",
"      Wang CC. Improved local control of nasopharyngeal carcinoma after intracavitary brachytherapy boost. Am J Clin Oncol 1991; 14:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17525/abstract/11\">",
"      Mazeron JJ, Belkacemi Y, Simon JM, et al. Place of Iridium 192 implantation in definitive irradiation of faucial arch squamous cell carcinomas. Int J Radiat Oncol Biol Phys 1993; 27:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17525/abstract/12\">",
"      Nag S, Cano ER, Demanes DJ, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 2001; 50:1190.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3406 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17525=[""].join("\n");
var outline_f17_7_17525=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H841867\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EXTERNAL BEAM RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Linear accelerators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1493365036\">",
"      Imaging for treatment planning and setup",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H163948839\">",
"      Three-dimensional conformal RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1493365078\">",
"      - Intensity-modulated RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1493365692\">",
"      - Image-guided RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1493365739\">",
"      - Treatment replanning and adaptive RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BRACHYTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H841867\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/35/24114?source=related_link\">",
"      Patient information: Brachytherapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=related_link\">",
"      Proton and ion beams in cancer therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_7_17526="Bupropion: Patient drug information";
var content_f17_7_17526=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bupropion: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     see \"Bupropion: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/11/39096?source=see_link\">",
"     see \"Bupropion: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aplenzin&trade;;",
"     </li>",
"     <li>",
"      Budeprion SR&reg;;",
"     </li>",
"     <li>",
"      Budeprion XL&reg; [DSC];",
"     </li>",
"     <li>",
"      Buproban&reg;;",
"     </li>",
"     <li>",
"      Forfivo&trade; XL;",
"     </li>",
"     <li>",
"      Wellbutrin SR&reg;;",
"     </li>",
"     <li>",
"      Wellbutrin XL&reg;;",
"     </li>",
"     <li>",
"      Wellbutrin&reg;;",
"     </li>",
"     <li>",
"      Zyban&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ava-Bupropion SR;",
"     </li>",
"     <li>",
"      Bupropion SR&reg;;",
"     </li>",
"     <li>",
"      Novo-Bupropion SR;",
"     </li>",
"     <li>",
"      PMS-Bupropion SR;",
"     </li>",
"     <li>",
"      ratio-Bupropion SR;",
"     </li>",
"     <li>",
"      Sandoz-Bupropion SR;",
"     </li>",
"     <li>",
"      Wellbutrin&reg; SR;",
"     </li>",
"     <li>",
"      Wellbutrin&reg; XL;",
"     </li>",
"     <li>",
"      Zyban&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700844",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       When used to stop smoking this drug may cause or make diseases of the mind worse. Taking one's own life, ideas of killing yourself or murder, low mood (depression), forceful actions, hallucinations, and psychoses have happened with use. If you think you have any of these problems, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chance of seizures may be higher. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691383",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help you stop smoking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691738",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat attention deficit problems with hyperactivity.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701664",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bupropion or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703516",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Eating problem or seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have some heart tests before starting this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696950",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use Aplenzin&trade;, Forfivo&trade; XL, Wellbutrin&reg;, or Zyban&reg; at the same time. They are the same drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you abuse beer, wine, mixed drinks, or cocaine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often if you have heart disease or are taking a product to replace nicotine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698205",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may see the tablet shell in your stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698156",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hot flashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have not been able to quit smoking after taking this drug for 12 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698697",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are new or worse after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696331",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may take this drug for 1 week before you stop smoking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nicotine products and counseling may be used at the same time for best results.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take tablet early in the day to stop sleep problems. Take at least 6 hours before bedtime.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11509 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17526=[""].join("\n");
var outline_f17_7_17526=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143210\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143211\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011289\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011291\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011290\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011295\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011296\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011298\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011293\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011294\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011299\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011300\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=related_link\">",
"      Bupropion: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/11/39096?source=related_link\">",
"      Bupropion: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_7_17527="Dermatofibroma - dark skin";
var content_f17_7_17527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatofibroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This oval, hyperpigmented, firm papule is a dermatofibroma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17527=[""].join("\n");
var outline_f17_7_17527=null;
var title_f17_7_17528="Rib anatomy and external landmarks";
var content_f17_7_17528=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 632px\">",
"   <div class=\"ttl\">",
"    Rib anatomy and external landmarks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 612px; height: 455px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clay JH, Pounds DM. Basic Clinical Massage Therapy: Integrating Anatomy and Treatment. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17528=[""].join("\n");
var outline_f17_7_17528=null;
var title_f17_7_17529="Management of abnormal uterine bleeding in adolescents";
var content_f17_7_17529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of abnormal uterine bleeding in adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/7/17529/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17529/contributors\">",
"     Nirupama K De Silva, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/7/17529/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17529/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17529/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/7/17529/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17529/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/7/17529/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menstrual disorders and abnormal uterine bleeding (AUB) are among the most frequent gynecologic complaints of adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/1\">",
"     1",
"    </a>",
"    ]. AUB refers to bleeding that is excessive or occurs outside of normal cyclic menstruation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/2\">",
"     2",
"    </a>",
"    ]. AUB is described by a variety of terms and may be caused by a number of genital and nongenital tract diseases, systemic disorders, and medications (",
"    <a class=\"graphic graphic_table graphicRef62751 \" href=\"UTD.htm?29/4/29773\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"     \"Overview of causes of genital tract bleeding in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment for these disorders ranges from observation to pharmacologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical therapy. Potential sequelae of AUB include anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/3\">",
"     3",
"    </a>",
"    ] and endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/4\">",
"     4",
"    </a>",
"    ]. With appropriate management of the underlying problem, these sequelae may be prevented. Thus, it is crucial to establish the correct diagnosis before any therapy is administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=see_link\">",
"     \"Definition and evaluation of abnormal uterine bleeding in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=see_link\">",
"     \"Differential diagnosis and approach to the adolescent with abnormal uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of AUB in adolescents will be discussed here. The evaluation of AUB in adolescents is discussed separately, as are the evaluation and management of AUB in premenopausal women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=see_link\">",
"     \"Definition and evaluation of abnormal uterine bleeding in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=see_link\">",
"     \"Differential diagnosis and approach to the adolescent with abnormal uterine bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The discussion below primarily pertains to AUB in otherwise healthy adolescents. The management of AUB in adolescents who have chronic disease, underlying coagulation disorders, or are undergoing chemotherapy, solid organ, or hematopoietic stem cell transplantation is beyond the scope of this discussion. Such patients should be managed in conjunction with the appropriate subspecialist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37285?source=see_link\">",
"     \"Heavy or irregular uterine bleeding during chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal uterine bleeding (AUB) in adolescents may be caused by a number of underlying problems (",
"    <a class=\"graphic graphic_table graphicRef62751 \" href=\"UTD.htm?29/4/29773\">",
"     table 1",
"    </a>",
"    ). AUB for which an underlying pathologic condition cannot be identified is known as dysfunctional uterine bleeding (DUB). Anovulatory bleeding is the primary cause for DUB in the adolescent population, and thus, \"anovulatory uterine bleeding\" is the term preferred by the American College of Obstetricians and Gynecologists [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When an underlying problem is identified, appropriate treatment of the underlying problem usually permits return to a normal menstrual pattern. The treatment for the various underlying conditions that may cause AUB in adolescents is discussed in the appropriate topic review. The remainder of the discussion in this topic review centers on the treatment of DUB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24297?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of DUB has several goals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Establishment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      maintenance of hemodynamic stability",
"     </li>",
"     <li>",
"      Correction of acute or chronic anemia",
"     </li>",
"     <li>",
"      Return to a pattern of normal menstrual cycles",
"     </li>",
"     <li>",
"      Prevention of recurrence",
"     </li>",
"     <li>",
"      Prevention of long-term consequences of anovulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of DUB varies according to its severity. However, some general principles apply regardless of severity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy (including ectopic pregnancy) and pelvic infections should be excluded before treatment is initiated [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      All adolescents treated for DUB should maintain a menstrual calendar (",
"      <a class=\"graphic graphic_figure graphicRef76376 \" href=\"UTD.htm?36/52/37710\">",
"       figure 1",
"      </a>",
"      ) to monitor subsequent episodes of DUB, as well as response to therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      All patients with DUB are at risk for iron deficiency anemia and should be monitored and treated accordingly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link\">",
"       \"Iron requirements and iron deficiency in adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Long-term monitoring and follow-up are necessary to prevent the potential sequelae of DUB (eg, anemia, infertility, endometrial cancer).",
"     </li>",
"     <li>",
"      Additional evaluation and consultation should be obtained if bleeding cannot be controlled despite hormonal therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In adolescents with DUB and sustained acyclic estrogen secretion, bleeding occurs when the endometrium becomes unstable (ie, when the endometrium proliferates beyond estrogen's ability to maintain its integrity). The administration of estrogen heals the sites of endometrial bleeding by causing further endometrial proliferation and provides hemostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. The administration of progesterone stops endometrial proliferation, stabilizes the endometrial lining, and promotes expulsion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rationale for hormonal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision of whether to observe girls with DUB or to treat them with hormonal therapy depends upon patient and guardian considerations, as well as the severity and chronicity of the DUB [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. The primary purpose of hormonal treatment is to stabilize endometrial proliferation and promote cyclic shedding. More than 90 percent of adolescents with DUB respond to hormonal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/10\">",
"     10",
"    </a>",
"    ]. Among those who do not, an alternative diagnosis (eg, bleeding disorder, polycystic ovary syndrome, infection, uterine pathology) should be considered. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Acute management'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=see_link&amp;anchor=H6#H6\">",
"     \"Definition and evaluation of abnormal uterine bleeding in adolescents\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=see_link\">",
"     \"Differential diagnosis and approach to the adolescent with abnormal uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Choice of agent(s)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of agent(s) and route of therapy depend upon the severity of bleeding and the need for contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/7\">",
"     7",
"    </a>",
"    ]. Unless there are contraindications, estrogen should be used in all patients who are actively bleeding because it promotes hemostasis. Estrogen is usually administered in combination with progestin. However, intravenous estrogen (without progestin) may be used initially in unstable patients who are actively bleeding and cannot take oral medications. Progestin (without estrogen) may be used to mature and slough the endometrium in patients who are not actively bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/8\">",
"     8",
"    </a>",
"    ] and who do not desire contraception. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Severe DUB'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although progestin-only and",
"    <span class=\"nowrap\">",
"     estrogen/progestin",
"    </span>",
"    combinations are frequently used in the management of DUB, the regime, dose, and type of progestin used varies widely with little consensus about the optimum treatment approach [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/11\">",
"     11",
"    </a>",
"    ]. There is a paucity of randomized studies relating to the use of these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ACUTE MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mild dysfunctional uterine bleeding (DUB)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild DUB is defined as longer than normal menses or shortened cycles for more than two months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5\">",
"     5",
"    </a>",
"    ]. Management of mild DUB consists of observation and reassurance. Girls with mild DUB should be asked to keep a menstrual calendar (",
"    <a class=\"graphic graphic_figure graphicRef76376 \" href=\"UTD.htm?36/52/37710\">",
"     figure 1",
"    </a>",
"    ) and can be given the option to avoid treatment with hormonal therapy. They should follow up in three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/12\">",
"     12",
"    </a>",
"    ] unless bleeding becomes more severe, in which case they should be seen acutely.",
"   </p>",
"   <p>",
"    Although hemoglobin concentration is usually normal (&gt;12",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    in mild DUB, iron supplementation (60 mg elemental iron per day) can be used to treat mild, asymptomatic anemia. Girls with mild DUB and hemoglobin between 10 and 12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    may also benefit from hormonal therapy as recommended for moderate DUB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link\">",
"     \"Iron requirements and iron deficiency in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Moderate DUB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate DUB is characterized by moderately prolonged or frequent menses every one to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5\">",
"     5",
"    </a>",
"    ]. Menstrual flow is moderate to heavy. Mild anemia (hemoglobin 10 to 12",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    is often present but without signs of hypovolemia or hemodynamic instability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/13\">",
"     13",
"    </a>",
"    ]. Moderate DUB can usually be managed in the outpatient setting.",
"   </p>",
"   <p>",
"    The treatment of moderate DUB typically involves hormonal therapy to stabilize endometrial proliferation and shedding. The choice of agent(s) depends, to some extent, upon how heavily the patient is bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/7\">",
"     7",
"    </a>",
"    ]. Girls with moderate DUB should be provided with iron supplementation (over-the-counter prenatal vitamins contain an adequate dose). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link\">",
"     \"Iron requirements and iron deficiency in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Moderate DUB, not currently bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with moderate DUB who are not actively bleeding may be offered the option of using combined hormonal contraception or progesterone-only hormonal contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/14\">",
"     14",
"    </a>",
"    ]. For the progestin-only regimens, many options are available including progesterone pills, depot",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/49/36631?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    shot, and copper or levonorgestrel-releasing intrauterine devices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=see_link\">",
"     \"Progestin-only pills (minipills) for contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link\">",
"     \"Depot medroxyprogesterone acetate for contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Progesterone-only pills include medroxyprogesterone (10 mg per day for the first 10 to 12 days each month) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/7,8,14\">",
"     7,8,14",
"    </a>",
"    ], or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/60/9158?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    (5 mg per day for the first 10 to 12 days each month), but we prefer micronized oral progesterone. We prefer micronized progesterone because it is chemically identical to endogenous progesterone and thus mimics the body's natural hormone.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Micronized oral progesterone (200 mg) is prescribed once per day for the first 12 days of each calendar month. This schedule is easier for teenagers to remember than the one described below.",
"     </li>",
"     <li>",
"      An alternative regimen is based upon the patient's menstrual cycle rather than the calendar month. Micronized oral progesterone (200 mg) is taken for 12 days beginning on the 14",
"      <sup>",
"       th",
"      </sup>",
"      day of the patient's menstrual cycle (day one is the first day of the last period). If bleeding occurs before the 14",
"      <sup>",
"       th",
"      </sup>",
"      day of the cycle, the patient should begin the medication on the 10",
"      <sup>",
"       th",
"      </sup>",
"      day of the cycle, or switch to the combination oral contraceptive (OC) regimen described above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If bleeding occurs during the progesterone course, the patient should discontinue progesterone and allow menses to occur. Bleeding usually begins two to three days after the last dose of progesterone, but may be delayed for up to one week. If the patient does not have menses within one week after the last dose of progesterone, exogenous hormones should be discontinued and an endocrinology evaluation initiated. The evaluation typically includes follicle-stimulating hormone, luteinizing hormone, prolactin, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, free and total testosterone, thyroid-stimulating hormone, and fasting insulin and glucose to evaluate potential disorders of the hypothalamic-pituitary-ovarian axis, polycystic ovary syndrome, and the metabolic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Moderate DUB, currently bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have complaints of heavy vaginal bleeding and no contraindications to estrogen use may have a better response to OCs that have a combination of estrogen and progestin rather than to progestin-only preparations, as estrogen provides hemostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. Monophasic OCs (ie, pills that contain the same dose of estrogen and progestin in each of the hormonally active pills) with a minimum of 30 mcg ethinyl estradiol&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef69223 \" href=\"UTD.htm?10/59/11184\">",
"     table 2",
"    </a>",
"    ) should be used in order to ensure a sufficient amount of estrogen is provided to prevent breakthrough bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link\">",
"     \"Overview of the use of estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As mentioned above, there is a paucity of data from randomized trials regarding the treatment of DUB in adolescents. Nonetheless, there are a variety of regimens that appear to be equally effective. We suggest that OC pills be taken three times per day until the bleeding ceases (usually within 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/7\">",
"     7",
"    </a>",
"    ]) and then tapered to twice daily for five days, and then decreased to once daily to complete 21 days of hormone therapy.",
"   </p>",
"   <p>",
"    If bleeding recurs when the dose is decreased to once per day, twice per day dosing may be necessary for the full 21 days. Close follow-up is essential during twice-per-day dosing. High-dose estrogen therapy can cause nausea, which may result in noncompliance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5\">",
"     5",
"    </a>",
"    ]. Antiemetic therapy (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/27/2487?source=see_link\">",
"     promethazine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    ) is often required before each dose of the pill [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5\">",
"     5",
"    </a>",
"    ]. The risks and side effects associated with estrogen-progestin contraceptives are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42201?source=see_link&amp;anchor=H17#H17\">",
"     \"Contraception: Overview of issues specific to adolescents\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of hormonal therapy after the initial 21-day course and the schedule of follow-up are discussed below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Long-term management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Progestin-only therapy is an alternative for girls with moderate DUB who cannot tolerate, dislike, or have a contraindication to estrogen therapy (eg, arterial or venous thromboembolic disease, estrogen-dependent tumors, hepatic dysfunction). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Moderate DUB, not currently bleeding'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Duration of therapy and follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should continue therapy for six months, after which hormonal therapy can be discontinued to determine whether a normal menstrual pattern has been established [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/15\">",
"     15",
"    </a>",
"    ]. A menstrual calendar should be maintained to monitor subsequent episodes of DUB. Such a calendar, if appropriately highlighted, can serve to remind girls on which days to take their medication.",
"   </p>",
"   <p>",
"    Girls treated with progestin therapy or combined hormonal contraceptives should return for follow-up in three months. If irregular or heavy bleeding persists despite three months of therapy, an endocrinology evaluation is warranted. The evaluation typically includes follicle-stimulating hormone, luteinizing hormone, prolactin, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, free and total testosterone, thyroid-stimulating hormone, and fasting insulin and glucose to evaluate potential disorders of the hypothalamic-pituitary-ovarian axis and polycystic ovary syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike combination OC pills, oral progestin-only derivatives do not reliably prevent ovulation. Thus, adolescents being treated with oral progesterone should be instructed to use other methods of contraception. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42201?source=see_link\">",
"     \"Contraception: Overview of issues specific to adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Severe DUB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe dysfunctional uterine bleeding (DUB) is defined by disruptive menstrual cycles with heavy bleeding that causes a decrease in hemoglobin (to &lt;10",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and may or may not cause hemodynamic instability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. Treatment of severe DUB may entail hospitalization for stabilization of hemodynamic status, blood transfusion, pharmacologic therapy, and, rarely, surgical therapy. Ultrasonography, examination under anesthesia, and dilation and curettage (D&amp;C) may be necessary to exclude pelvic pathology if the various hormonal and hemostatic regimens described below fail to control bleeding within 24 to 36 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iron supplementation should be initiated as soon as the patient is stable and able to take pills by mouth. Depending upon the severity of iron deficiency, 60 mg of elemental iron (eg, one prenatal vitamin) should be administered once or twice per day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link\">",
"     \"Iron requirements and iron deficiency in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalization is necessary for patients who are hemodynamically unstable, who have low hemoglobin concentration, or who have symptomatic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. Indications for hospitalization include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initial hemoglobin &lt;7",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Orthostatic signs",
"     </li>",
"     <li>",
"      Heavy active bleeding and hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (if the hemoglobin is between 8 and 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      <strong>",
"       and",
"      </strong>",
"      the patient is hemodynamically stable",
"      <strong>",
"       and",
"      </strong>",
"      the patient and family are reliable",
"      <strong>",
"       and",
"      </strong>",
"      can maintain close telephone contact, home management may be possible with daily monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5\">",
"       5",
"      </a>",
"      ])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The need for blood transfusion must be assessed on a case-by-case basis depending upon the hemoglobin, blood loss, orthostatic vital signs, and the ability to rapidly gain control of bleeding through prompt administration of intravenous fluid, plasma expanders, and hormonal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5,13\">",
"     5,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Girls who require hospitalization for DUB should undergo evaluation for a bleeding disorder. Menorrhagia requiring hospitalization or transfusion may be the initial presentation of coagulation disorder, particularly von Willebrand disease. Blood for evaluation of bleeding disorders should be obtained before administration of blood products or estrogen (exogenous estrogen may elevate von Willebrand factor [VWF] into the normal range) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=see_link&amp;anchor=H10#H10\">",
"     \"Differential diagnosis and approach to the adolescent with abnormal uterine bleeding\", section on 'Menorrhagia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation for girls who require hospitalization for menorrhagia within the first 12 months of menarche should include platelet count, platelet function analyzer, examination of the peripheral blood smear, prothrombin time (PT), activated partial thromboplastin time (aPTT), plasma VWF antigen, plasma VWF activity (ristocetin cofactor activity), factor VIII activity, and blood group typing (blood group O is associated with lower levels of VWF), and thyroid-stimulating hormone (TSH). The evaluation for girls who require hospitalization for DUB more than 12 months after menarche should include, at a minimum, a screening for hypothyroidism (TSH), PT, and aPTT. Any underlying disorder that is detected should be promptly treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H17#H17\">",
"     \"Platelet function testing\", section on 'The platelet function analyzer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hormonal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several hormonal therapy options for girls with severe DUB. Combination OC pills with high-dose estrogen are usually the first-line therapy. Progestin-only is an alternative for patients in whom estrogen is contraindicated or who object to taking combination OCs. Intravenous estrogen therapy is typically reserved for unstable patients who cannot take oral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5\">",
"     5",
"    </a>",
"    ]. The risks and side effects associated with estrogen-progestin contraceptives are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42201?source=see_link&amp;anchor=H17#H17\">",
"     \"Contraception: Overview of issues specific to adolescents\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13138678\">",
"    <span class=\"h4\">",
"     Combination OC pills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy typically includes a monophasic combination OC pill with 50 mcg estradiol and 0.5 mg norgestrel or 50 mcg estradiol and 1 mg",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/60/9158?source=see_link\">",
"     norethindrone",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef69223 \" href=\"UTD.htm?10/59/11184\">",
"     table 2",
"    </a>",
"    ) administered according to various schedules:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The schedule we prefer is a high-dose combination pill every four hours until the bleeding subsides (usually within 24 hours), then four times per day for four days, then three times per day for three days, then two times a day for two weeks. It is essential to make sure that the adolescent knows NOT to take the placebo pills.",
"     </li>",
"     <li>",
"      An alternative schedule uses estradiol (50",
"      <span class=\"nowrap\">",
"       mcg)/norgestrel",
"      </span>",
"      (0.5 mg) every four hours until the bleeding stops (usually within 24 hours), then every six hours for 24 hours, then every eight hours for 48 hours, then twice per day to complete a 21-day course of hormones.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Addition of intravenous conjugated estrogen therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/32/14854?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    , discussed below, should be considered if the bleeding is not controlled within 24 hours.",
"   </p>",
"   <p>",
"    If bleeding recurs during tapering, the dose of OC pills should be increased to the lowest dose that controls bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/7\">",
"     7",
"    </a>",
"    ]. Antiemetic therapy (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/27/2487?source=see_link\">",
"     promethazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    ) may be required for girls who are taking more than one pill per day.",
"   </p>",
"   <p>",
"    Management of hormonal therapy after the initial tapering and the schedule of follow-up are discussed below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Long-term management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13138703\">",
"    <span class=\"h4\">",
"     Progestin-only pills",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who can take oral medications but in whom high-dose estrogen is contraindicated (eg, arterial or venous thromboembolic disease, estrogen-dependent tumors, and hepatic dysfunction or disease), one of the following progestin-only regimens may be tried:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/60/9158?source=see_link\">",
"       Norethindrone acetate",
"      </a>",
"      (5 to 10 mg),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Micronized progesterone (200 mg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients should be instructed to take one pill every four hours until the bleeding stops. Once the bleeding stops, they can take one pill four times a day for four days, then three times a day for three days, then twice a day for two weeks.",
"   </p>",
"   <p>",
"    In patients in whom estrogen is contraindicated and progestin-only regimens fail to control the bleeding,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/32/14854?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"     desmopressin",
"    </a>",
"    may be initiated. If bleeding is not controlled after the addition of hemostatic agents, surgical intervention is indicated. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Hemostatic therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Surgical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Management of hormonal therapy once bleeding is controlled and the schedule of follow-up are discussed below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Long-term management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13138710\">",
"    <span class=\"h4\">",
"     Conjugated estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous conjugated equine estrogen may be necessary for some patients (eg, those who are unstable",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unable to take oral medications). It&nbsp;may be used in lieu of&nbsp;combination OC pills until the&nbsp;bleeding is stopped.&nbsp;Once the bleeding has resolved, the patient should be switched to a combination OC that contains at least 50 mcg of estradiol.",
"   </p>",
"   <p>",
"    The effectiveness of intravenous estrogen was demonstrated in a double-blind trial in which 34 patients with DUB were randomly assigned to intravenous treatment with intravenous conjugated equine estrogen (25 mg IV every four hours for up to 24 hours) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/16\">",
"     16",
"    </a>",
"    ]. Intravenous conjugated estrogen treatment successfully controlled bleeding in 72 percent of patients compared with 38 percent of those given placebo. In most cases, bleeding diminished within three hours of initiating hormone therapy.",
"   </p>",
"   <p>",
"    The dose of intravenous conjugated estrogen is 25 mg every four to six hours until the bleeding stops. No more than six doses should be administered. Because pulmonary embolism is a potential complication of intravenous estrogen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/17\">",
"     17",
"    </a>",
"    ], the minimum effective dose to control bleeding should be administered. As with any high-dose estrogen treatment, antiemetics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/27/2487?source=see_link\">",
"     promethazine",
"    </a>",
"    12.5 to 25 mg orally, transdermally, or per rectum) should be prescribed one hour before each dose to alleviate side effects of nausea and vomiting.",
"   </p>",
"   <p>",
"    Bleeding usually subsides within 4 to 24 hours of the initiation of IV estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/8\">",
"     8",
"    </a>",
"    ]. If bleeding lasts longer than 24 to 48 hours after initiation of IV estrogen, oral progesterone should be added to stabilize the endometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5,12\">",
"     5,12",
"    </a>",
"    ].&nbsp;Hemostatic therapy, as described below, should be considered if bleeding persists beyond 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/7\">",
"     7",
"    </a>",
"    ]. Once the bleeding has resolved, the patient should be switched to a combination OC that contains at least 50 mcg of estradiol.",
"   </p>",
"   <p>",
"    Management of hormonal therapy once bleeding is controlled and the schedule of follow-up are discussed below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Long-term management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hemostatic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases of severe menorrhagia unresponsive to 24 hours of hormonal therapy or in those with platelet dysfunction, nonhormonal hemostatic drugs may be used [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/18\">",
"     18",
"    </a>",
"    ]. These include the antifibrinolytic compounds,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/32/14854?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/49/8982?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"     desmopressin",
"    </a>",
"    , which is classically used for the treatment of von Willebrand disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/32/14854?source=see_link\">",
"     Aminocaproic acid",
"    </a>",
"    may be administered orally or intravenously as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/32/14854?source=see_link\">",
"       Aminocaproic acid",
"      </a>",
"      5 g orally (ten 500 mg tablets or 4 teaspoonfuls (20 mL) of syrup (1.25",
"      <span class=\"nowrap\">",
"       g/5",
"      </span>",
"      mL)) during the first hour, followed by a continuing dose of 1 to 1.25 g (two 500 mg tablets or 1 teaspoonful (5 mL) of syrup) per hour. Treatment is continued for approximately 8 hours or until the bleeding has been controlled,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/32/14854?source=see_link\">",
"       Aminocaproic acid",
"      </a>",
"      , 4 to 5 g IV (16 to 20 mL of 250",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      solution in 250 mL diluent) during the first hour of treatment, followed by a continuing infusion at a rate of 1 g (4 mL of 250",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in 50 mL diluent) per hour. Treatment is continued for approximately 8 hours or until the bleeding has been controlled.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"     Desmopressin",
"    </a>",
"    is administered intravenously as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"       Desmopressin",
"      </a>",
"      0.3",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      IV over 15 to 30 minutes. The dose may be repeated in 48 hours if there is no response. The nasal route of administration is not recommended for acute bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilation and curettage (D&amp;C) is rarely required as a diagnostic or treatment tool in adolescents. It should be reserved for the rare patient who continues to bleed heavily despite adequate hormonal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/9\">",
"     9",
"    </a>",
"    ] or who is unable to take estrogen. If D&amp;C is performed in adolescents, care must be taken to prevent Asherman syndrome (scarring of the endometrial lining). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\", section on 'Dilation and curettage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Discharge criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient may be discharged to home when the bleeding has stopped and she is hemodynamically stable. Close follow-up must be maintained after discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     LONG-TERM MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management after the acute episode of bleeding is controlled and the initial course of hormonal therapy is complete depends upon the presence of persistent anemia and the desire for contraception. Low-dose combination oral contraception (OC) pills should be continued in girls who desire contraception and in those who required IV conjugated estrogen for initial control. Micronized oral progesterone therapy may be used in girls with moderate or severe dysfunctional uterine bleeding (DUB) who were initially controlled with progestin-only regimens and do not desire contraception.",
"   </p>",
"   <p>",
"    As a general rule, hormonal therapy is continued for three to six months, unless the adolescent wishes to continue because she is sexually active or happy with the effects of the hormonal therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Combination OC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regimens described below are general guidelines. Adjustments may be necessary depending upon efficacy and the adolescent's tolerance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In girls without significant anemia (hemoglobin &gt;10",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      monophasic combination OCs with at least 30 mcg ethinyl estradiol should be continued cyclically (eg, 21 days of hormone-containing pills, followed by seven days of placebo pills or no pills to induce withdrawal bleeding) for three to six months.",
"     </li>",
"     <li>",
"      In girls with significant anemia (hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL),",
"      </span>",
"      monophasic combination OCs with at least 30 mcg ethinyl estradiol may be taken continuously to avoid withdrawal menses until the hemoglobin concentration has returned toward normal [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5,7\">",
"       5,7",
"      </a>",
"      ]. The authors suggest continuous therapy for at least three months, monitoring hemoglobin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hematocrit monthly until the concentration returns to normal. Continuous OC therapy should be followed by cyclic therapy to complete a total of six months. When continuous hormonal therapy is desired, it may be helpful to prescribe 21-day packages or to remove the placebo pills from 28-day packs so the adolescent does not inadvertently take hormone-free pills [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/7\">",
"       7",
"      </a>",
"      ]. The adolescent should be warned that menstrual flow during the initial withdrawal period will be heavier than normal [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/7\">",
"       7",
"      </a>",
"      ]. Withdrawal bleeding typically begins two to four days after the last hormone-containing pills are taken [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/5\">",
"       5",
"      </a>",
"      ]. This bleeding may be heavier than normal, but should not last longer than seven days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hormonal therapy with combination OC pills can be discontinued after three to six months to determine whether a normal menstrual pattern has been established [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/15\">",
"     15",
"    </a>",
"    ]. However, combination OC pills need not be discontinued in sexually active adolescents or in those adolescents who wish to continue them.",
"   </p>",
"   <p>",
"    A menstrual calendar (",
"    <a class=\"graphic graphic_figure graphicRef76376 \" href=\"UTD.htm?36/52/37710\">",
"     figure 1",
"    </a>",
"    ) should be maintained to monitor subsequent episodes of DUB. Such a calendar, if appropriately highlighted, can serve to remind girls on which days to take their medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Progestin-only",
"    </span>",
"    &nbsp;&mdash;&nbsp;Girls in whom progestin-only regimens were used to control DUB should continue progesterone therapy for six months, after which hormonal therapy can be discontinued to determine whether a normal menstrual pattern has been established [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/15\">",
"     15",
"    </a>",
"    ]. The regimen is the same as it is for girls with moderate DUB who are not actively bleeding (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Moderate DUB'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Micronized oral progesterone (200 mg per day) for the first 12 days of each calendar month or for 12 days beginning on the 14th day of the menstrual cycle.",
"     </li>",
"     <li>",
"      An alternate regimen preferred by some practitioners is medroxyprogesterone (10 mg per day) for the first 10 to 12 days of each month.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A menstrual calendar (",
"    <a class=\"graphic graphic_figure graphicRef76376 \" href=\"UTD.htm?36/52/37710\">",
"     figure 1",
"    </a>",
"    ) should be maintained to monitor subsequent episodes of DUB. Such a calendar, if appropriately highlighted, can serve to remind girls on which days to take their medication.",
"   </p>",
"   <p>",
"    Oral progestin-only derivatives do not reliably prevent ovulation. Thus, adolescents being treated with oral progesterone should be instructed to use other methods of contraception. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42201?source=see_link\">",
"     \"Contraception: Overview of issues specific to adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild DUB should be followed up in three to six months. Those with moderate or severe DUB require closer follow-up. They should be seen one to two months after the initial episode, depending upon the severity of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, during the acute phase, when they are taking &ge;60 mcg estradiol per day, phone follow-up should be maintained to ensure compliance.",
"   </p>",
"   <p>",
"    Long-term follow-up of girls with a history of anovulatory cycles is essential. Regular endometrial shedding, induced by progesterone withdrawal, protects against the development of endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once hormonal therapy has been discontinued, girls who go more than three months without a period (and are not pregnant) should undergo a hormonal workup and should receive progesterone to induce withdrawal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/12\">",
"     12",
"    </a>",
"    ]. We use micronized oral progesterone (200 mg) nightly for 12 days per month. The adolescent is asked to induce menses at least every three months or to restart combined hormonal contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/12\">",
"     12",
"    </a>",
"    ]. The endocrine evaluation typically includes follicle-stimulating hormone, luteinizing hormone, prolactin, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, free and total testosterone, thyroid-stimulating hormone, and fasting insulin and glucose to evaluate potential disorders of the hypothalamic-pituitary-ovarian axis and polycystic ovary syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic anovulation (greater than two to three years in duration) is associated with endometrial hyperplasia and increased risk of endometrial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/21\">",
"     21",
"    </a>",
"    ]. Concomitantly, obesity promotes peripheral conversion of androgens to estrogens, further enhancing endometrial growth. Endometrial biopsy should be considered in adolescents who have a history of two to three years of",
"    <strong>",
"     untreated",
"    </strong>",
"    anovulatory bleeding, particularly if they are obese or have a family history of endometrial, ovarian, breast, or colon cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H2#H2\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, dysfunctional uterine bleeding (DUB) should resolve with maturation of the hypothalamic-pituitary-ovarian axis. The duration of time that it takes to attain maturity (regular, ovulatory cycles) appears to be related to the age of menarche. In girls who begin menses at &lt;12 years, between 12 and 13 years, and &gt;13 years of age, 50 percent of cycles are ovulatory by one year, three years, and 4.5 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/23\">",
"     23",
"    </a>",
"    ]. An individual's normal cycle length, however, is not established until her sixth gynecological year, at the average age of 19 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term prognosis for girls with AUB depends upon the underlying cause [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/7\">",
"     7",
"    </a>",
"    ]. Girls with a long history of anovulatory cycles and DUB, particularly those with polycystic ovary syndrome (PCOS), have an increased risk of later infertility and endometrial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17529/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of management of abnormal uterine bleeding (AUB) in adolescents is return to a pattern of normal menstrual cycles and prevention of long-term sequelae. Whenever it is possible to determine an underlying etiology of AUB (",
"    <a class=\"graphic graphic_table graphicRef62751 \" href=\"UTD.htm?29/4/29773\">",
"     table 1",
"    </a>",
"    ), appropriate treatment of the underlying problem usually permits return to a normal menstrual pattern. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    A variety of regimens may be used depending upon whether the patient is actively bleeding, hemodynamically unstable,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    able to take oral medications. There are few studies comparing these regimens to each other or to placebo.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild dysfunctional uterine bleeding (DUB) can usually be managed with iron supplementation and observation. Hormonal therapy is usually necessary for moderate or severe DUB. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Mild dysfunctional uterine bleeding (DUB)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adolescents with moderate DUB who are not actively bleeding and hemodynamically stable may be treated with progestin alone. The regimen preferred by the authors is micronized oral progesterone (200 mg once per day for the first 12 days of each calendar month). These patients also should receive iron supplementation if there is evidence of anemia. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Moderate DUB, not currently bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adolescents with moderate DUB who are actively bleeding may have a better response to monophasic combination oral contraception (OC) with a minimum of 30 mcg ethinyl estradiol&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef69223 \" href=\"UTD.htm?10/59/11184\">",
"       table 2",
"      </a>",
"      ). The pills should be taken twice per day until the bleeding stops and then continued once per day. These patients also should receive iron supplementation if there is evidence of anemia. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Moderate DUB, currently bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adolescents with severe DUB usually require an increased dose of estrogen. The authors prefer a monophasic combination OC with 50 microgram estradiol and 0.5 mg norgestrel (",
"      <a class=\"graphic graphic_table graphicRef69223 \" href=\"UTD.htm?10/59/11184\">",
"       table 2",
"      </a>",
"      ). We recommend the OC be taken every four hours until the bleeding subsides, then four times per day for four days, then three times per day for three days, then two times a day for two weeks. Iron supplementation should be initiated as soon as the patient is hemodynamically stable. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Severe DUB'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13138678\">",
"       'Combination OC pills'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients in whom high-dose estrogen is contraindicated, a progestin-only regimen (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/60/9158?source=see_link\">",
"       norethindrone acetate",
"      </a>",
"      (5 to 10 mg) or micronized progesterone (200 mg)) may be tried. Patients should take one pill every four hours until the bleeding stops, and then one pill four times a day for four days, three times a day for three days, and twice a day for two weeks. (See",
"      <a class=\"local\" href=\"#H13138703\">",
"       'Progestin-only pills'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous conjugated equine estrogen may be necessary for some patients with severe DUB (eg, those who are unstable and unable to take oral medications). The dose is 25 mg every six hours for up to six doses or until the bleeding stops. Antiemetics should be prescribed one hour before each dose to alleviate side effects of nausea and vomiting (need to add progestin within 24 to 48 hours). (See",
"      <a class=\"local\" href=\"#H13138710\">",
"       'Conjugated estrogen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Red blood cell transfusion may be necessary for patients who are hemodynamically unstable, have extremely low hemoglobin concentrations, or have symptomatic anemia. Peripheral blood should be obtained from the patient for evaluation of bleeding disorders, including von Willebrand disease, before the blood is transfused. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Severe DUB'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term follow-up is essential. Hormonal treatment should be continued for at least three to six months when possible. Once hormonal therapy has been discontinued, girls who go more than three months without a period (and are not pregnant) should undergo an endocrinology workup and receive a course of progesterone to induce withdrawal bleeding. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Long-term management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28543813\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Robert Zurawin, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/1\">",
"      Caufriez A. Menstrual disorders in adolescence: pathophysiology and treatment. Horm Res 1991; 36:156.",
"     </a>",
"    </li>",
"    <li>",
"     APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/3\">",
"      ACOG Committee on Adolescent Health Care. ACOG Committee Opinion No. 349, November 2006: Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Obstet Gynecol 2006; 108:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/4\">",
"      ACOG Committee on Practice Bulletins--Gynecology. American College of Obstetricians and Gynecologists.. ACOG practice bulletin: management of anovulatory bleeding. Int J Gynaecol Obstet 2001; 72:263.",
"     </a>",
"    </li>",
"    <li>",
"     Gray SH, Emans SJ. Abnormal vaginal bleeding in the adolescent. In: Emans, Laufer, Goldstein's Pediatric &amp; Adolescent Gynecology, 6th, Emans SJ, Laufer MR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. p.159.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/6\">",
"      Adams Hillard PJ, Deitch HR. Menstrual disorders in the college age female. Pediatr Clin North Am 2005; 52:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/7\">",
"      Rimsza ME. Dysfunctional uterine bleeding. Pediatr Rev 2002; 23:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/8\">",
"      Cowan BD, Morrison JC. Management of abnormal genital bleeding in girls and women. N Engl J Med 1991; 324:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/9\">",
"      Slap GB. Menstrual disorders in adolescence. Best Pract Res Clin Obstet Gynaecol 2003; 17:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/10\">",
"      Strickland JL, Wall JW. Abnormal uterine bleeding in adolescents. Obstet Gynecol Clin North Am 2003; 30:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/11\">",
"      Hickey M, Higham J, Fraser IS. Progestogens versus oestrogens and progestogens for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev 2000; :CD001895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/12\">",
"      Bravender T, Emans SJ. Menstrual disorders. Dysfunctional uterine bleeding. Pediatr Clin North Am 1999; 46:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/13\">",
"      Mitan LA, Slap GB. Adolescent menstrual disorders. Update. Med Clin North Am 2000; 84:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/14\">",
"      Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol 1990; 30:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/15\">",
"      Strickland J, Gibson EJ, Levine SB. Dysfunctional uterine bleeding in adolescents. J Pediatr Adolesc Gynecol 2006; 19:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/16\">",
"      DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding--a double-blind randomized control study. Obstet Gynecol 1982; 59:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/17\">",
"      Zreik TG, Odunsi K, Cass I, et al. A case of fatal pulmonary thromboembolism associated with the use of intravenous estrogen therapy. Fertil Steril 1999; 71:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/18\">",
"      Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/19\">",
"      Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/20\">",
"      Whitehead MI, Townsend PT, Pryse-Davies J, et al. Effects of various types and dosages of progestogens on the postmenopausal endometrium. J Reprod Med 1982; 27:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/21\">",
"      Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983; 61:403.",
"     </a>",
"    </li>",
"    <li>",
"     ACOG Practice Bulletin. Management of anovulatory bleeding, Number 14, March 2000 in Compendium of Selected Publications 2004. p.434.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/23\">",
"      Apter D, Vihko R. Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles. J Clin Endocrinol Metab 1983; 57:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/24\">",
"      American Academy of Pediatrics Committee on Adolescence, American College of Obstetricians and Gynecologists Committee on Adolescent Health Care, Diaz A, et al. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics 2006; 118:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17529/abstract/25\">",
"      Southam AL, Richart RM. The prognosis for adolescents with menstrual abnormalities. Am J Obstet Gynecol 1966; 94:637.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 117 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-23EAA62341-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17529=[""].join("\n");
var outline_f17_7_17529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rationale for hormonal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Choice of agent(s)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACUTE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mild dysfunctional uterine bleeding (DUB)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Moderate DUB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Moderate DUB, not currently bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Moderate DUB, currently bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Duration of therapy and follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Severe DUB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hormonal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13138678\">",
"      Combination OC pills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13138703\">",
"      Progestin-only pills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13138710\">",
"      Conjugated estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hemostatic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Discharge criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      LONG-TERM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Combination OC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Progestin-only",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28543813\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/117\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/117|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/52/37710\" title=\"figure 1\">",
"      Menstrual calendar",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/117|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/4/29773\" title=\"table 1\">",
"      Causes abnormal uterine bleeding teen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/59/11184\" title=\"table 2\">",
"      Estrogen and progestin types and doses in hormonal contraceptive",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=related_link\">",
"      Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=related_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42201?source=related_link\">",
"      Contraception: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=related_link\">",
"      Definition and evaluation of abnormal uterine bleeding in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=related_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=related_link\">",
"      Differential diagnosis and approach to the adolescent with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37285?source=related_link\">",
"      Heavy or irregular uterine bleeding during chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=related_link\">",
"      Iron requirements and iron deficiency in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=related_link\">",
"      Overview of causes of genital tract bleeding in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=related_link\">",
"      Progestin-only pills (minipills) for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=related_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24297?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_7_17530="Vaginal pessary treatment of prolapse and incontinence";
var content_f17_7_17530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vaginal pessary treatment of prolapse and incontinence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/7/17530/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17530/contributors\">",
"     Jeffrey L Clemons, MD, LTC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/7/17530/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17530/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/7/17530/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/7/17530/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/7/17530/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic organ prolapse (POP) and stress urinary incontinence (SUI) are common conditions, with prevalence rates of 25 to 65 and 20 to 55 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Surgical repair is one approach to treatment: approximately 200,000 women undergo surgery for POP and 135,000 women undergo surgery for SUI annually in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], and approximately 11 percent of women undergo surgery for POP or SUI by age 80; 30 percent of these women will have repeat surgery because of persistent or recurrent symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaginal pessaries are an alternative treatment option for women with these conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pessary trial can be offered to all women with pelvic organ prolapse (POP) or stress urinary incontinence (SUI), regardless of patient characteristics. Clinical settings where pessary use should be considered include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient preference for nonsurgical treatment.",
"     </li>",
"     <li>",
"      Presence of severe medical comorbidities that make the patient a poor surgical candidate.",
"     </li>",
"     <li>",
"      Need to delay surgery for several weeks or months.",
"     </li>",
"     <li>",
"      Recurrent POP or SUI and patient preference for avoidance of repeat surgery. However, prior prolapse surgery and prior hysterectomy are risk factors for failure to fit a pessary (see",
"      <a class=\"local\" href=\"#H31\">",
"       'Risk factors for an inability to fit a pessary'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Vaginal ulcerations caused by severe POP. Reduction of POP through use of a pessary and application of vaginal estrogen cream both promote healing of the ulcers within three to six weeks, which is useful prior to surgical repair.",
"     </li>",
"     <li>",
"      Current pregnancy, to manage POP and cervical insufficiency.",
"     </li>",
"     <li>",
"      Desire for future childbearing. The benefit of surgical repair of POP may be nullified by subsequent pregnancy and childbirth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATIENT ACCEPTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient acceptance of pessaries varies from 42 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10-13\">",
"     10-13",
"    </a>",
"    ], and is related to appropriate counseling and encouragement from the provider. Patients who decline a pessary trial are more likely to be nulliparous [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/11\">",
"     11",
"    </a>",
"    ], younger [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], or have severe prolapse and incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/12\">",
"     12",
"    </a>",
"    ]. This was illustrated in two studies of treatment choices among women with pelvic organ prolapse (POP) that found older women were more likely than younger women to choose a pessary, whereas women with prior prolapse surgery, more severe prolapse, and more severe symptoms related to bowel emptying, sexual function, and quality of life were more likely to choose surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to pessary use are rarely encountered. Potential contraindications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local infection &ndash; Active infections of the vagina or pelvis, such as vaginitis or pelvic inflammatory disease, preclude the use of a pessary until the infection has been resolved.",
"     </li>",
"     <li>",
"      Exposed foreign body &ndash; An exposed foreign body such as vaginal mesh should preclude pessary use until the exposure of the foreign body has been resolved.",
"     </li>",
"     <li>",
"      Latex sensitivity &ndash; The Inflatoball pessary is made of latex; therefore, it is contraindicated in women with latex allergies. The other pessaries discussed below are nonallergenic.",
"     </li>",
"     <li>",
"      Noncompliance &ndash; Noncompliance with follow-up could be harmful since an undetected and untreated erosion could put the patient at risk of developing a fistula.",
"     </li>",
"     <li>",
"      Sexually active women who are unable to remove and reinsert the pessary &ndash; Inability to manage the pessary around coital activity could be discouraging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TYPES OF PESSARIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pessaries come in several different shapes and sizes (",
"    <a class=\"graphic graphic_picture graphicRef73252 \" href=\"UTD.htm?25/33/26128\">",
"     picture 1",
"    </a>",
"    ). Most are made of silicone, which is nonallergenic, durable, autoclavable, and does not retain odors. A few are made of other materials, such as latex or polycarbonate. Pessaries are available from: Milex&trade;, Cooper Surgical, Trumbull, CT; Bioteque America, Inc, Langhorne, PA; Artisan Medical, Medford, NJ; and Marina Medical, Sunrise, FL. There are also a few incontinence pessaries, designed specifically for the treatment of stress urinary incontinence (SUI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Support versus space filling pessaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pessaries can be classified into essentially two categories: support and space-filling. The support pessary is used to treat all stages of pelvic organ prolapse (POP) and SUI, whereas the space-filling pessary is mostly used for severe POP. Both types are held in place proximally by the uterus (or the vaginal apex following hysterectomy), laterally by the levator muscles, and distally by the pubic bone and the vaginal introitus. Space-filling pessaries and larger size pessaries are often needed for severe prolapse (stage III or IV), as vaginal capacity can increase significantly as a result of levator atrophy and an enlarged vaginal introitus can allow a support pessary to rotate and be expelled.",
"   </p>",
"   <p>",
"    Surveys of gynecologists [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/15\">",
"     15",
"    </a>",
"    ] and urogynecologists [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/16\">",
"     16",
"    </a>",
"    ] showed that the ring pessary (support type pessary) was the most commonly used pessary. A prospective observational study reported that most women with stage II and III prolapse (100 and 71 percent, respectively) were successfully fitted with ring pessaries, whereas women with stage IV prolapse usually required a Gellhorn pessary (space-filling pessary) (64 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10\">",
"     10",
"    </a>",
"    ]. A randomized crossover trial compared the 'ring with support' to Gellhorn pessary in women with stage II-IV prolapse and showed significant improvement in prolapse, urinary, and rectal symptoms with both, and no difference in symptom response between pessaries [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    I suggest initial use of a support pessary, rather than a space-filling pessary, because support pessaries are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      More easily removed and inserted by the patient",
"     </li>",
"     <li>",
"      Allow intercourse while in place",
"     </li>",
"     <li>",
"      Are often more comfortable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    I routinely use the 'ring with support' or Gellhorn pessary, as most women with prolapse can be managed with ring sizes 3, 4, and 5 and Gellhorn sizes 2.5, 2.75, and 3 inches [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10\">",
"     10",
"    </a>",
"    ], and, as discussed above, they are equally effective for the treatment of prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In unusual cases of prolapse, a double pessary may be used [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Support pessaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Support pessaries are essentially two-dimensional, and sit in the long axis of the vagina. Types of support pessaries include the ring (with or without a support diaphragm), the lever, the Gehrung, the Shaatz, and the incontinence ring or dish pessaries. Most women can remove and reinsert support pessaries. Sexual intercourse is still possible when they are left in place.",
"   </p>",
"   <p>",
"    Ring pessaries are the only support pessaries that I use, as use of only one type of support pessary is practical and the lever, Gehrung, and Shaatz pessaries have minimal added benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Ring pessaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ring pessary, as in Letters F, G and L in the picture (",
"    <a class=\"graphic graphic_picture graphicRef73252 \" href=\"UTD.htm?25/33/26128\">",
"     picture 1",
"    </a>",
"    ), will fit 70 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10\">",
"     10",
"    </a>",
"    ]. It is the most commonly used pessary, as it can treat all stages of POP, as well as SUI [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,15,16\">",
"     10,15,16",
"    </a>",
"    ]. Additionally, it is comfortable, easily removed and inserted by the patient, and sexual intercourse is possible when left in place. A string may be attached to the ring to aid in removal; this string should be tucked into the vagina to avoid soiling with urine and feces. However, the ring can usually be removed easily without a string.",
"   </p>",
"   <p>",
"    The 'ring with support' pessary has a thin diaphragm across the ring, and is especially useful for women with uterine prolapse",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cystocele, but may also be used to treat rectocele and vaginal vault prolapse. Although the ring pessary is available in sizes 0 to 9, most women can be managed with sizes 3, 4, and 5 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ring pessary is inserted by folding it in half like a taco, and then inserting it with the curved side up (",
"    <a class=\"graphic graphic_figure graphicRef81223 \" href=\"UTD.htm?24/20/24897\">",
"     figure 1",
"    </a>",
"    ). The ring will then open to its circular shape. The lower rim of the pessary should rest behind the pubic symphysis (",
"    <a class=\"graphic graphic_figure graphicRef69208 \" href=\"UTD.htm?3/61/4048\">",
"     figure 2",
"    </a>",
"    ). The ring should then be turned one-quarter turn, so that it will not easily fold onto itself and be expelled.",
"   </p>",
"   <p>",
"    The 'ring without support' pessary is useful in younger women, as they have less atrophy of the levator muscles, and a more oval contour to the vagina. The absence of the support diaphragm allows this pessary to take an oval shape and conform to the shape of the vagina.",
"   </p>",
"   <p>",
"    The incontinence ring pessary has a knob that is placed beneath the urethra to increase urethral pressure when treating SUI (",
"    <a class=\"graphic graphic_figure graphicRef76369 \" href=\"UTD.htm?31/34/32289\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lever pessaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Smith, Hodge, and Risser pessaries, as in Letters A, B, C, and E in the picture (",
"    <a class=\"graphic graphic_picture graphicRef73252 \" href=\"UTD.htm?25/33/26128\">",
"     picture 1",
"    </a>",
"    ), are collectively referred to as lever pessaries. These devices were originally intended to treat uterine retroversion. They may be used for uterine prolapse and cystocele, and case reports have described use in pregnancies complicated by cervical insufficiency. They are no longer commonly used.",
"   </p>",
"   <p>",
"    When inserting a lever pessary, the uterus is manually anteverted if it has been retrodisplaced. The pessary is then folded and inserted into the vagina. The index finger is placed against the posterior bar until it rests posterior to the cervix. The anterior bar should rest posteriorly to the pubic symphysis (",
"    <a class=\"graphic graphic_figure graphicRef68708 \" href=\"UTD.htm?36/7/36977\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Gehrung pessary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Gehrung pessary is designed to treat cystocele",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rectocele. It has a U-shaped flexible rim with a rubber diaphragm, as in Letter D in the picture (",
"    <a class=\"graphic graphic_picture graphicRef73252 \" href=\"UTD.htm?25/33/26128\">",
"     picture 1",
"    </a>",
"    ). When inserted properly, the two bases rest on the posterior vagina against the lateral levator muscles, and the concave surface and diaphragm support the anterior vagina. There are no studies of this pessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Shaatz pessary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Shaatz pessary is a rigid ring pessary, and essentially the same as the Gellhorn pessary without the stem (ie, just the base of the Gellhorn), as in Letter I in the picture (",
"    <a class=\"graphic graphic_picture graphicRef73252 \" href=\"UTD.htm?25/33/26128\">",
"     picture 1",
"    </a>",
"    ). It does not fold, so must be inserted vertically and then rotated to a horizontal position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Space-filling pessaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Space-filling pessaries are essentially three-dimensional, and differ from the support pessaries in that they have a large base that supports the vaginal apex (or cervix). They include the Gellhorn, donut, cube, inflatoball, and Colpexin sphere pessaries. They are often needed in women with severe (stage III or IV) POP, especially post-hysterectomy vaginal vault prolapse, but offer no advantage in the treatment of SUI. Space-filling pessaries are often difficult for patients to remove, and sexual intercourse is not possible when they are in place. To simplify office management, I mostly use the flexible Gellhorn pessaries, but occasionally use the other space-filling pessaries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Gellhorn pessary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Gellhorn pessary has a broad, firm, circular base with a stem protruding from the center, as in Letter K in the picture (",
"    <a class=\"graphic graphic_picture graphicRef73252 \" href=\"UTD.htm?25/33/26128\">",
"     picture 1",
"    </a>",
"    ). The broad base provides support to the vaginal apex, and the stem sits on the long axis of the vagina. The stem keeps the circular base from rotating into the long axis of the vagina and being expelled (",
"    <a class=\"graphic graphic_figure graphicRef54046 \" href=\"UTD.htm?41/13/42207\">",
"     figure 5",
"    </a>",
"    ). The base is slightly concave, allowing suction to form against the vagina, which helps hold the pessary in place, but can make it difficult to remove manually. There are small holes in the base to allow drainage, as well as a hole in the stem (",
"    <a class=\"graphic graphic_picture graphicRef81272 \" href=\"UTD.htm?35/26/36271\">",
"     picture 2",
"    </a>",
"    ). The Gellhorn sizes reflect the diameter of the base and are available in 1.5 to 3.5 inch sizes, in one-quarter-inch increments. Most women can be managed with the 2.5, 2.75, and 3-inch sizes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Gellhorn pessary is inserted by first holding the stem and partially folding one side of the base up to the stem, so that the base of the pessary is vertical and at a 90-degree angle to the introitus. (Folding the base up to the stem gives the Gellhorn more of a two-dimensional shape). A finger from the opposite hand separates the introitus and depresses the perineal body. The leading edge of the base is placed into the vagina until it reaches the apex, then rotated so that the base supports the apex and the stem is in the long axis of the vagina.",
"   </p>",
"   <p>",
"    A Kelly clamp can be used to grasp the stem to assist with removal (one jaw of the clamp is inserted into the hole and the other jaw grasps the outside of the stem). The flexible Gellhorn is better than the rigid Gellhorn, as placement is easier. A string may be attached to the stem to aid in removal. This string should be tucked into the vagina to avoid soiling with urine and feces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Donut pessary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The donut pessary is similar to a ring pessary, but the ring is thick and hollow, as in Letter N in the picture (",
"    <a class=\"graphic graphic_picture graphicRef73252 \" href=\"UTD.htm?25/33/26128\">",
"     picture 1",
"    </a>",
"    ). The thick, hollow ring fills the larger space associated with advanced prolapse and levator atrophy. The donut pessary is available in diameter sizes similar to the Gellhorn, ranging from 1- to 3-inch sizes, in one-quarter-inch increments. Most women needing a donut pessary can be managed with the 2.5, 2.75, and 3-inch sizes.",
"   </p>",
"   <p>",
"    The donut pessary is inserted by holding it vertically (",
"    <a class=\"graphic graphic_figure graphicRef61016 \" href=\"UTD.htm?31/10/31919\">",
"     figure 6",
"    </a>",
"    ) and then rotating it to a horizontal position during placement. A Kelly clamp may be required for pessary removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cube pessary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cube pessary has six concave sides, as in Letter H in the first picture (",
"    <a class=\"graphic graphic_picture graphicRef73252 \" href=\"UTD.htm?25/33/26128\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65730 \" href=\"UTD.htm?37/10/38051\">",
"     picture 3",
"    </a>",
"    ), which allow the Cube to hold the vaginal walls with suction, thereby preventing prolapse (",
"    <a class=\"graphic graphic_figure graphicRef81498 \" href=\"UTD.htm?40/23/41330\">",
"     figure 7",
"    </a>",
"    ). Although the Cube is highly effective in correcting prolapse, the risk of a neglected cube pessary is high because even short-term use is associated with a profound malodorous discharge and vaginal erosions. To minimize occurrence of these problems, the Cube pessary should be removed nightly, cleaned, and not reinserted until the next morning.",
"   </p>",
"   <p>",
"    The Cube pessary is inserted by squeezing the flexible rubber sides together and then placing the device at the vaginal apex. It is available in sizes 0 to 7, with diameters ranging from 1 to 2.25 inches. Again, a string may be attached to aid in removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Inflatable pessary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Inflatoball pessary was designed to facilitate removal and insertion by the patient, as in Letter M in the picture (",
"    <a class=\"graphic graphic_picture graphicRef73252 \" href=\"UTD.htm?25/33/26128\">",
"     picture 1",
"    </a>",
"    ). It has an air-filled ball and a stem with a port; a bulb is attached to the port to inflate or deflate the pessary, which makes the device less bulky during insertion and removal. However, the stem protrudes from the vagina and may cause unacceptable discomfort. Additionally, the pessary is made of latex, not silicone, so it cannot be used in women with latex allergy.",
"   </p>",
"   <p>",
"    The Inflatoball is placed in a similar manner as the donut pessary. The bulb is then attached, a ball-bearing within the stem is moved to a lateral projection on the side of the stem, the pessary is inflated, the ball-bearing is moved back into position to keep the pessary inflated, and the bulb is removed (",
"    <a class=\"graphic graphic_figure graphicRef69101 \" href=\"UTD.htm?20/22/20833\">",
"     figure 8",
"    </a>",
"    ). The Inflatoball pessary is available in diameter sizes of 2 to 2.75 inches, in one-quarter-inch increments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Spherical pessary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Colpexin&reg; Sphere (Adamed, Warsaw, Poland) is a newer pessary designed to make removal and insertion easier, improve comfort (because of its smaller size and spherical shape), and allow the patient to perform concomitant pelvic floor muscle exercises (",
"    <a class=\"graphic graphic_figure graphicRef69336 \" href=\"UTD.htm?1/2/1056\">",
"     figure 9",
"    </a>",
"    ). It is made of polycarbonate, with an attached braided nylon string for ease of removal, and is available in six sizes, from 28 mm to 44 mm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Incontinence pessaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few pessaries designed specifically for SUI. They include incontinence ring and incontinence dish pessaries, the Uresta&trade; incontinence pessary, the Contiform&trade; intravaginal device, the Cook&reg; Continence Ring, the Introl&reg; bladder neck support prosthesis, and the ConTIPI disposable intravaginal device.",
"   </p>",
"   <p>",
"    When fitted properly, an incontinence pessary compresses the urethra against the upper posterior portion of the symphysis pubis, causing an increase in urethral resistance that prevents leakage associated with sudden increases in abdominal pressure (ie, cough or valsalva).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Incontinence ring and dish",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incontinence ring pessary, as in Letter L in the picture (",
"    <a class=\"graphic graphic_picture graphicRef73252 \" href=\"UTD.htm?25/33/26128\">",
"     picture 1",
"    </a>",
"    ), has a knob that is placed beneath the urethra to increase urethral pressure to treat stress incontinence (",
"    <a class=\"graphic graphic_figure graphicRef76369 \" href=\"UTD.htm?31/34/32289\">",
"     figure 3",
"    </a>",
"    ). The incontinence dish is more rigid and shaped like a dish, but has minimal added benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Bell-shaped incontinence pessary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Uresta&trade; incontinence pessary is a bell-shaped pessary with a handle at its base for easy removal and insertion. It has a narrow, rounded tip that allows easy insertion into the vaginal introitus. When properly positioned, the wide base supports the urethra. It is made of a medical grade rubber that has been extensively tested for biocompatibility and safety, and available in sizes 3, 4, and 5 (small, medium, and large).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Cylindrical intravaginal device",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Contiform&trade; intravaginal device is shaped like a large, hollow tampon made of Santoprene&trade;, a nonallergenic thermoplastic rubber. The device sits behind the pubic bone and supports the urethra during episodes of increased intraabdominal pressure. Its tampon-like shape was partly designed to facilitate",
"    <span class=\"nowrap\">",
"     self-insertion/removal",
"    </span>",
"    by patients. This pessary can be ordered only in or from Australia or New Zealand [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Continence Ring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cook&reg; Continence Ring (Spencer, IN) is only available from the manufacturer with a doctor's letter. It is a flexible ring pessary with an inflatable balloon that lies under the urethrovesical junction. The balloon obstructs the flow of urine during rest and episodes of physical stress. When the patient experiences an urge to void, or when a specified time interval on a voiding schedule has passed, the balloon is deflated to allow voiding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Disposable intravaginal device",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ConTIPI disposable intravaginal device is made of a flexible resin core with a cover made of soft nylon mesh, which provides support to the urethra whenever abdominal pressure is transferred to the pelvic floor. The device is inserted with an applicator, similar to a tampon, and a cotton string is attached to the mesh cover for removal. Among 60 women with severe SUI, 85 percent were markedly improved [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PESSARY FITTING TRIAL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Fitting the pessary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women to be fitted for a pessary are first examined with an empty bladder in the dorsal lithotomy position. Post-void urine residual is assessed and urine is sent for urinalysis. A split speculum exam using the pelvic organ prolapse quantitation system (POP-Q) is used to stage the prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/22\">",
"     22",
"    </a>",
"    ] and assess vaginal atrophy. Pelvic floor muscle strength (Kegel squeeze) is also evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=see_link\">",
"     \"Pelvic organ prolapse in women: Diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaginal introitus size, vaginal length, and prolapse stage are used to guide selection of pessary type and size. However, pessary fitting is mostly a trial and error process, and several pessaries may be needed to obtain an adequate fit. Ultimately, the largest pessary that is comfortable is prescribed.",
"   </p>",
"   <p>",
"    The type of pessary likely to be needed is determined by measuring prolapse stage and the size of the vaginal introitus, the latter is gauged by the number of fingerbreadths accommodated across the posterior fourchette (this is typically 1 to 4 fingers) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10\">",
"     10",
"    </a>",
"    ]. If the vaginal introitus size is 1 to 2 fingerbreadths and the prolapse stage is II-III, a ring pessary is likely to be successful, whereas with a 3 to 4 fingerbreadth introitus or stage IV prolapse, a Gellhorn pessary is more likely to be successful [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10\">",
"     10",
"    </a>",
"    ]. Next, the size of the pessary that will be needed is estimated by inserting two fingers to measure the width and length of the vagina (",
"    <a class=\"graphic graphic_figure graphicRef74477 \" href=\"UTD.htm?38/48/39681\">",
"     figure 10",
"    </a>",
"    ). It is important to get an overall estimate of the vaginal length and vaginal width together. If the vaginal length has been shortened by a prior hysterectomy, or if the vaginal width has been narrowed by a prior prolapse surgery, then only smaller size pessaries will fit.",
"   </p>",
"   <p>",
"    Pessaries are inserted into the vagina with the dominant hand, while the nondominant hand separates the introitus and depresses the perineal body. A nonlubricated glove is used, and a small amount of lubricant is applied to the leading edge of the pessary; if too much lubricant is used, the pessary will be too slippery to control. After the pessary is inserted into the vagina, the woman is asked to strain and cough repeatedly on the examination table, ambulate in the office, and void and strain while sitting on a toilet. This \"office trial\" helps determine if she will be able to retain the pessary and void when she returns home, and if bothersome urinary incontinence will develop. She should have a negative cough stress test following pessary placement, as she is unlikely to be satisfied if there are significant stress urinary incontinence (SUI) symptoms.",
"   </p>",
"   <p>",
"    Women should be reassured that it is not an emergency if the pessary is expelled; they should just bring the pessary back to the office and a different type or size of pessary will likely be effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;A follow-up visit is scheduled one to two weeks later. The patient is asked if there were any side effects, such as discomfort, expulsion, persistent bulge or pressure symptoms, persistent or de novo stress or urge urinary incontinence, difficulty with urination or bowel movements, or vaginal bleeding or discharge.",
"   </p>",
"   <p>",
"    The pessary is removed and cleaned with soap and water, and the vagina is examined for erosions. If the pessary fits well and there were no side effects, motivated and able patients are taught how to remove, clean, and reinsert their pessary. The pessary should be removed, cleaned, and left out over night every one to two weeks; it should also be removed before sexual intercourse. The patient should be seen for second follow-up visit in one to two months, and every 12 months thereafter.",
"   </p>",
"   <p>",
"    If the patient cannot, or chooses not, to remove and reinsert her pessary, then she should return for follow-up in one to two months, and every three to six months thereafter for pessary cleaning and assessment by the clinician. A survey of 555 clinicians that use pessaries in the United Kingdom reported that 23 percent changed their patients pessaries every three to six months, 67 percent every six months, and 10 percent every 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, we offer most women low-dose estrogen vaginal cream (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/23/35184?source=see_link\">",
"     conjugated equine estrogens",
"    </a>",
"    cream [CEE] 0.25 to 0.5 g, two to three nights per week) to treat co-existing vaginal atrophy and dryness from estrogen deficiency.",
"   </p>",
"   <p>",
"    In some women, the width of the introitus may decrease in size after several weeks of pessary use. In such women, a new smaller size pessary is prescribed to allow for easier removal and insertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Management of side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;If bothersome side effects occur, then pessary use is either discontinued, or the patient is fit with a different size or type of pessary and asked to return again in one to two weeks, or medical therapy is prescribed, if appropriate.",
"   </p>",
"   <p>",
"    Vaginal erosions and ulcers are reported in 3 to 24 percent of women (weighted mean 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,12,24,25\">",
"     10,12,24,25",
"    </a>",
"    ]. Other common side effects include vaginal bleeding, development of a malodorous vaginal discharge, and irritative symptoms. These minor complications usually occur in the setting of vaginal atrophy, and can be treated or prevented with medical therapy.",
"   </p>",
"   <p>",
"    A malodorous discharge is typically due to bacteria from the rectum that has migrated to the vagina. Enteric bacteria will not typically colonize the vagina in premenopausal women due to the low pH (4.0 to 4.5). Following menopause, the lack of estrogen leads to absence of vaginal lactobacilli, so the pH becomes neutral. This creates a hospitable environment for enteric bacteria and may result in a vaginal discharge.",
"   </p>",
"   <p>",
"    If vaginal atrophy and discharge are the main problems, treatment with vaginal estrogen cream (eg, CEE 0.25 to 0.5 g, two to three nights a week) or a vaginal product that results in an acidic pH (eg, Trimo-San gel) promotes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     lactobacillus",
"    </a>",
"    and restricts rectal bacteria growth. If vaginal atrophy is severe or vaginal erosions are present, I use a higher dose of vaginal estrogen (CEE 0.5 to 1 g nightly) and continue pessary use, with follow-up examinations every one to two weeks until the vagina heals.",
"   </p>",
"   <p>",
"    Other common side effects from pessary use include de novo (occult) stress urinary incontinence, interference with sexual intercourse, and difficulty with bowel movements. Urinary tract infections have been reported in 13 percent of pessary users, and bacterial vaginosis in up to 32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/12,24,26,27\">",
"     12,24,26,27",
"    </a>",
"    ]. Some women may need to stop pessary use temporarily, or be fitted with another size or type of pessary, or consider surgical treatment of their prolapse or stress incontinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Duration of use and replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pessary use may be continued indefinitely. A change in the pessary type or size may be needed as a woman ages. The pessary does not need to be replaced if it becomes discolored, but a new pessary should be given if it becomes cracked or loses its shape and strength.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Pessary fitting trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several cohort studies were reviewed to determine the outcome of pessary fitting trials in women with prolapse and urinary incontinence. Nine studies were prospective [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,17,25,28-33\">",
"     10,17,25,28-33",
"    </a>",
"    ] and 10 were retrospective [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/11,24,26,34-40\">",
"     11,24,26,34-40",
"    </a>",
"    ]. They varied in the types of pessaries used (support only, space-filling only, or both), prolapse severity, indication for pessary (prolapse only, incontinence only, or both), time to first follow-up visit (one to four weeks), and study site (urogynecology practice or nurse pessary clinic) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,11,17,24-26,28-40\">",
"     10,11,17,24-26,28-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcomes were reported using one or more of three denominators: (1) all women offered a pessary (intention-to-treat), (2) only women who were fitted with a pessary at the first visit, or (3) women with a successful pessary fitting trial (ie, woman is fitted (or refitted) with a pessary and decides at the follow-up visit to continue use). Weighted averages and ranges were calculated for several outcomes, and the main findings are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At the first visit, 85 percent (range 71 to 94 percent) of women were fitted with a pessary [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,11,17,24,25,28,29,33-37\">",
"       10,11,17,24,25,28,29,33-37",
"      </a>",
"      ]. On average, two to three pessaries were tried before obtaining an adequate fit [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,11,24\">",
"       10,11,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For women with prolapse, ring pessaries (sizes 3,4,5) were used in 70 to 74 percent, and space-filling pessaries (Gellhorn and donut) were used in 26 to 29 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,25,37\">",
"       10,25,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Refitting with a new pessary at the first follow-up visit was necessary in 29 to 40 percent of women, and was successful in 76 to 85 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,17,35,39\">",
"       10,17,35,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For women with incontinence, incontinence ring or dish pessaries were used in 78 to 100 percent, and ring pessaries were used in 0 to 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/11,24,33\">",
"       11,24,33",
"      </a>",
"      ]; in two studies, the Introl and Uresta incontinence pessaries were used [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A successful pessary fitting trial was achieved in 63 percent (range 41 to 86 percent) of all women (intention-to-treat, includes women initially unable to be fitted) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,11,17,24-26,28,29,31,33-35,37,40\">",
"       10,11,17,24-26,28,29,31,33-35,37,40",
"      </a>",
"      ], and 72 percent (range 24 to 95 percent) of women initially fitted with a pessary [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,11,17,24,25,28-36,39\">",
"       10,11,17,24,25,28-36,39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women with prolapse were as likely as women with incontinence to have a successful pessary fitting trial (71 and 76 percent, respectively). Common reasons for an unsuccessful pessary fitting trial were discomfort, expulsion, inadequate relief of prolapse symptoms, worsening or persistent urinary incontinence, de novo difficulty with voiding or defecation, and inconvenience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Risk factors for an inability to fit a pessary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common predictors of an unsuccessful pessary fitting trial are prior prolapse surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/11,24,26,34,35,41\">",
"     11,24,26,34,35,41",
"    </a>",
"    ], prior hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/11,30,34,35\">",
"     11,30,34,35",
"    </a>",
"    ], and concurrent pelvic organ prolapse (POP) and stress urinary incontinence (SUI) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/12,25,26,31,41\">",
"     12,25,26,31,41",
"    </a>",
"    ]. Related risk factors include short vaginal length (&lt;6 cm) and a wide vaginal introitus (over 4 fingerbreadths) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10\">",
"     10",
"    </a>",
"    ]. Prolapse surgery and hysterectomy alter the vaginal anatomy, potentially resulting in a shortened or narrowed vagina. Concurrent SUI may be difficult to treat when fitting a pessary for POP, as the pessary type and size that best treat the prolapse may fail to provide adequate support for the urethra.",
"   </p>",
"   <p>",
"    Less common risk factors for an unsuccessful pessary fitting trial include younger age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/25\">",
"     25",
"    </a>",
"    ], higher parity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/31\">",
"     31",
"    </a>",
"    ], and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/26\">",
"     26",
"    </a>",
"    ]. Sexual activity does not appear to be a risk factor for failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,31,35,36\">",
"     10,31,35,36",
"    </a>",
"    ]. Additionally, the following POP-Q exam parameters have been evaluated and found not to be risk factors for pessary failure: prolapse stage or grade (ie, severity) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,12,25,26,34,35\">",
"     10,12,25,26,34,35",
"    </a>",
"    ], the leading vaginal compartment of the prolapse (ie, anterior, apical, or posterior) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,34\">",
"     10,34",
"    </a>",
"    ], and genital hiatus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,11,33,34\">",
"     10,11,33,34",
"    </a>",
"    ]. Unfortunately, the POP-Q examination fails to address introital width, vaginal caliber, atrophy of pelvic floor muscles, and shape of the pelvic bones, all of which may influence pessary success.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Treatment of prolapse trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mostly short-term and medium-term outcomes of pessary treatment of POP have been published.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Satisfaction and continued use &mdash; In observational studies, short-term (two to six months) satisfaction and continued use was 81 percent (range 63 to 92 percent) for women with a successful pessary fitting trial, and 59 percent (range 40 to 77 percent) by intention-to-treat [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/17,25,26,35,37,42\">",
"       17,25,26,35,37,42",
"      </a>",
"      ]. Medium-term (one to two years) satisfaction and continued use was 62 percent (range 53 to 83 percent) for women with a successful pessary fitting trial, and 40 percent (range 30 to 63 percent) by intention-to-treat [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/12,17,25,26,37,38,41,43,44\">",
"       12,17,25,26,37,38,41,43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two conflicting long-term studies on continued pessary use have been published [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. A prospective observational study of 187 women from the United Kingdom showed a 86 percent continuation rate over five years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/46\">",
"       46",
"      </a>",
"      ], whereas a retrospective study of 167 women from Australia showed a continuation rate of 14 percent over 14 years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Symptom improvement &mdash; A single randomized trial that compared the 'ring with support' and Gellhorn pessary found similar improvement in symptoms after three months of use for both devices [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In observational studies, after two to four months of pessary use: 70 to 90 percent of prolapse symptoms resolved (bulge, pressure, splinting) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/17,30,42\">",
"     17,30,42",
"    </a>",
"    ], 40 to 50 percent of associated urinary symptoms resolved (stress and urge incontinence and voiding difficulty) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/17,25,31,42\">",
"     17,25,31,42",
"    </a>",
"    ], 30 to 50 percent of associated bowel symptoms resolved (anal incontinence, anal urgency, and obstructive symptoms) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/17,31\">",
"     17,31",
"    </a>",
"    ], and 40 to 60 percent of women reported increased sexual frequency and satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/31\">",
"     31",
"    </a>",
"    ]. However, pessary use is less effective than surgical repair of POP in improving sexual function, as measured by a validated sexual function questionnaire for women with POP [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Validated questionnaires &mdash; Three studies have demonstrated that Pelvic Floor Distress Inventory (PFDI) scores improved in women successfully treated with a pessary for POP, notably the urinary and prolapse scales, but not the colorectal scale [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/44,48,49\">",
"       44,48,49",
"      </a>",
"      ]. Interestingly, the Pelvic Floor Impact Questionnaire (PFIQ) scores did not change with pessary use in two studies [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/48,49\">",
"       48,49",
"      </a>",
"      ], but improved in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/44\">",
"       44",
"      </a>",
"      ]. Of note, one study also evaluated women treated with surgery for POP, and all six scales of the PFDI and PFIQ improved [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/48\">",
"       48",
"      </a>",
"      ]. One study has demonstrated that Sheffield POP scores improve similarly at one year in women with POP treated with pessary or surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anatomic changes &mdash; There are limited data on the anatomic changes following pessary use. One study reported a decrease in size of the genital hiatus (GH) after three months of pessary use, from 4.8 cm to 3.9 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/51\">",
"       51",
"      </a>",
"      ]. Another study reported an improvement in POP-Q stage in 21 percent of women after one year of use [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, it appears that correction of the vaginal prolapse with a vaginal pessary not only restores the vagina, bladder, and rectum to their normal positions to improve prolapse symptoms, but also improves many of the associated urinary, bowel, and sexual dysfunction symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Risk factors for discontinuing pessary use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for discontinuing pessary use in women with a successful pessary fitting trial for POP include: severe posterior vaginal prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/35,41,43\">",
"     35,41,43",
"    </a>",
"    ], development of occult SUI [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/42\">",
"     42",
"    </a>",
"    ], and desire for surgery at first visit [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/43\">",
"     43",
"    </a>",
"    ]. Although several studies have shown that prolapse stage or grade (ie, severity of POP) is not a risk factor for discontinued pessary use [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/25,26,38,43\">",
"     25,26,38,43",
"    </a>",
"    ], a rectocele in a woman with severe posterior vaginal prolapse may be less well supported by a pessary than a cystocele or vaginal vault prolapse, leading to dissatisfaction and discontinuation. Occult SUI (ie, de novo SUI that occurs with reduction of POP with the pessary) is a difficult problem to overcome, so women with this problem often prefer surgery (to correct both the POP and SUI) or expectant management to using a pessary.",
"   </p>",
"   <p>",
"    Conversely, the following have been identified as strong predictors of continued pessary use: age greater than 65 to 72 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/41,43\">",
"     41,43",
"    </a>",
"    ], women whose baseline PFDI-20 score decreased by 50 percent after two months of use [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/49\">",
"     49",
"    </a>",
"    ], and women who attain self-determined goals (ie, goals related to bladder function, physical activity, and general health) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Responses to a 1997 survey of American Urogynecologic Society members on contraindications to pessary treatment of prolapse included prior hysterectomy (42 percent), current sexual activity (45 percent), and hypoestrogenism (64 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/16\">",
"     16",
"    </a>",
"    ]. Interestingly, most studies have not excluded women with these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,12,17,24-26,31,34-38\">",
"     10,12,17,24-26,31,34-38",
"    </a>",
"    ]. Prior hysterectomy is not a risk factor for discontinued use [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/25,26,35,43\">",
"     25,26,35,43",
"    </a>",
"    ], although it has been identified as a risk factor for failure to fit a pessary [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/11,31,34,35\">",
"     11,31,34,35",
"    </a>",
"    ]. Sexual activity is not a risk factor for failure to fit [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,31,35,36\">",
"     10,31,35,36",
"    </a>",
"    ] or discontinued use [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/35,36,43\">",
"     35,36,43",
"    </a>",
"    ]. In fact, sexual activity predicted continued pessary use in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/36\">",
"     36",
"    </a>",
"    ], and another reported that 90 percent of sexually active women using a pessary were able to remain sexually active [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/42\">",
"     42",
"    </a>",
"    ]. Three studies recommended treatment of vaginal atrophy or erosions with more frequent use of estrogen cream (nightly), and weekly follow-up until the vagina healed, rather than excluding women with hypoestrogenism [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/10,12,25\">",
"     10,12,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Treatment of urinary incontinence trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of vaginal pessaries for urinary incontinence is related to improved urethral function. Urodynamic studies of women treated with a pessary for SUI have shown increases in functional urethral length [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/53\">",
"     53",
"    </a>",
"    ] and urethral closure pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/53-55\">",
"     53-55",
"    </a>",
"    ], absence of urethral obstruction to flow [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/53\">",
"     53",
"    </a>",
"    ], and resolution of detrusor instability in women with severe prolapse and detrusor instability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/56\">",
"     56",
"    </a>",
"    ]. Anatomically, pessaries improve urethral support, as there is a reduction in the straining Q-tip angle [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/54\">",
"     54",
"    </a>",
"    ], and dynamic magnetic resonance imaging studies show a decreased posterior urethrovesical angle, elevation of the bladder neck, and increased urethral lengths [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of stress incontinence with a pessary appears to be less successful than pelvic floor muscle training during the first few months of therapy; however, long-term use of either strategy is associated with similar outcomes. The highest quality data regarding this issue are from the Ambulatory Treatment for Leakage Associated with Stress Incontinence (ATLAS) randomized trial of 446 women with stress incontinence who were assigned to one of three treatment groups: continence pessary; behavioral therapy (pelvic floor muscle training and other strategies); or combined use of a pessary and behavioral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/57\">",
"     57",
"    </a>",
"    ]. At three months, significantly fewer women in the pessary versus behavioral or combined groups reported a complete absence of bothersome incontinence symptoms (pessary: 33 percent; behavioral: 49 percent; combined: 44 percent) and treatment satisfaction (63; 75; 79 percent); these outcomes did not differ significantly between the behavioral and combined groups. At 12 months, there were no significant differences among the pessary, behavioral, and combined groups in the proportion of women who reported an absence of incontinence symptoms (35; 40; 33 percent) or patient satisfaction (50; 54; 54 percent).",
"   </p>",
"   <p>",
"    In a secondary study from the ATLAS trial, among women successfully treated for SUI, improvement in continence during sexual activity was greater in the behavioral and combined groups than in the pessary group [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational studies have reported short-term efficacy (one month or less) of pessaries for stress and mixed urinary incontinence, with improvements in pad testing, bladder diaries, and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/43,59-61\">",
"     43,59-61",
"    </a>",
"    ]. A literature review reported a subjective",
"    <span class=\"nowrap\">",
"     cured/improved",
"    </span>",
"    rate of 63 percent after one month [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/62\">",
"     62",
"    </a>",
"    ]. Medium-term (6 to 13 months) satisfaction and continued use was 59 percent (range 39 to 76 percent) for women with a successful pessary fitting trial, and 43 percent (range 16 to 59 percent) by intention-to-treat [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/11,28,29,39,54\">",
"     11,28,29,39,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the ATLAS trial described above, women discontinued treatment in both the pessary and behavioral groups at similar rates at both three months (18 and 15 percent) and 12 months (27 and 32 percent); these rates exclude women who withdrew from the pessary group due to a failed pessary fitting.",
"   </p>",
"   <p>",
"    Other studies have reported that most women who chose not to continue using a pessary discontinued use within one to two months. The most common reasons given were persistent incontinence, resolution of incontinence with pelvic floor muscle exercises, and pessary discomfort or expulsion. Prior incontinence surgery was a risk factor for discontinued pessary use [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/28,39\">",
"     28,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continence pessaries or pelvic floor muscle training are typically used for women with stress incontinence who decline or are not candidates for more effective surgical treatments. Pelvic muscle floor training requires more time for a patient than pessary use. In contrast, exercises have no associated adverse effects, while pessary use may be accompanied by vaginal erosions and malodorous vaginal discharge. Given these clinical considerations and the ATLAS trial data, we suggest pelvic floor muscle training rather than continence pessary use for women with stress urinary incontinence who do not otherwise have a preference for one of these nonsurgical modalities and in women whose incontinence interferes with sexual function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     For prediction of surgical outcome",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary incontinence &mdash; Occult SUI has been reported in 27 to 68 percent of women with severe prolapse [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/63-67\">",
"       63-67",
"      </a>",
"      ]. A pessary placed during urodynamic evaluation of women with POP can diagnose occult (potential) SUI and predict whether anti-incontinence surgery will be therapeutic. This was illustrated in two studies of women with POP who underwent pessary placement as part of their preoperative evaluation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/66,67\">",
"       66,67",
"      </a>",
"      ]. Among those with a positive pessary test for occult SUI, postoperative SUI occurred in 41 to 65 percent of women who did not undergo a mid-urethral sling procedure at the time of prolapse surgery, but in only 9 to 11 percent of those who did undergo a mid-urethral sling. By comparison,",
"      <span class=\"nowrap\">",
"       0/30",
"      </span>",
"      women with a negative pessary test developed symptomatic SUI postoperatively. These observations are similar to those from another study which reported a 64 percent rate of postoperative SUI when prolapse surgery alone was performed in women with occult SUI [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/68\">",
"       68",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The Colpopexy and Urinary Reduction Efforts (CARE) trial randomized women with severe prolapse and absence of SUI to undergo abdominal sacrocolpopexy with or without concomitant Burch colposuspension [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/69\">",
"       69",
"      </a>",
"      ]. Women who received a Burch colposuspension had significantly fewer postoperative SUI symptoms, regardless of whether preoperative prolapse reduction testing demonstrated occult SUI. Whether this applies to other vaginal vault suspension or anti-incontinence surgeries is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relief of urinary obstruction &mdash; In another study, pessary reduction in women with severe anterior vaginal prolapse and urinary retention (post-void residual &gt;100 ml) predicted cure of urinary retention by prolapse surgery: 79 percent were cured by surgery, and the pessary was 89 percent sensitive [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/70\">",
"       70",
"      </a>",
"      ]. A similar study found urethral obstruction on urodynamic evaluation in 72 percent of women with grade 3 or 4 cystocele, with resolution of the obstruction in 94 percent following pessary insertion [",
"      <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious complications from vaginal pessary use are rare. A few case reports have described pessary incarceration, fistula from the bladder or rectum, urinary or colonic obstruction, and vaginal cancer in women with \"neglected\" pessaries [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/72-76\">",
"     72-76",
"    </a>",
"    ]. At risk patients are elderly women with cognitive difficulties who are unable to inform health care workers that they have a vaginal pessary in place. Such complications are usually avoidable with routine care and follow-up, although there is one report of a vesicovaginal fistula from a \"well-cared-for\" pessary [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/77\">",
"     77",
"    </a>",
"    ], and one report of an undiagnosed vaginal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/7/17530/abstract/78\">",
"     78",
"    </a>",
"    ]. Communication with the patient's family or caretakers is important to ensure that follow-up will be accomplished. Minor side effects are relatively common. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Management of side effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/62/44001?source=see_link\">",
"       \"Patient information: Pelvic organ prolapse (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/16/9474?source=see_link\">",
"       \"Patient information: Urinary incontinence in women (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=see_link\">",
"       \"Patient information: Urinary incontinence treatments for women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of pelvic organ prolapse (POP) or stress urinary incontinence (SUI) with a pessary is inexpensive, effective, and safe; contraindication to use and serious complications are rare.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pessary trial can be offered to most women with prolapse or urinary incontinence, regardless of patient characteristics. An exception is women with exposed foreign body following surgery for prolapse or urinary incontinence. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two basic types of pessaries: support pessaries (eg, ring) and space-filling pessaries (eg, Gellhorn). There are also a few pessaries designed specifically for urinary incontinence. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Types of pessaries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ring with support and Gellhorn pessaries are equally effective for the treatment of prolapse. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Support versus space filling pessaries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ring pessary will fit 70 percent of women. We suggest ring pessaries for most women, because they are comfortable, easily removed and inserted by the patient, and sexual intercourse is possible with the pessary left in place (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ring pessaries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pessary fitting is done by trial and error; the largest pessary comfortable for the patient is used. We suggest a ring pessary if the vaginal introitus size is 1 to 2 fingerbreadths and the prolapse stage is II-III. We suggest a Gellhorn pessary if the vaginal introitus is 3 to 4 fingerbreadths or there is stage IV prolapse (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Fitting the pessary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At the initial visit, approximately 85 percent of women with POP can be fitted with a pessary; two to three different pessaries may be needed before finding the best one. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Pessary fitting trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At the follow-up visit one to two weeks later, women are asked if there are side effects such as discomfort, expulsion, persistent bulge or pressure symptoms, persistent or de novo stress or urge urinary incontinence, difficulty with urination or bowel movements, or vaginal bleeding or discharge. In the absence of bothersome side effects, pessary use may be continued indefinitely. A change in the pessary type or size may be needed as a woman ages. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low dose estrogen vaginal cream may be used to treat co-existing vaginal atrophy or erosions. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Management of side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A successful pessary fitting occurs in approximately 70 percent of women fitted with a pessary. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Pessary fitting trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for failure to fit a pessary include prior prolapse surgery, prior hysterectomy, and concurrent POP and SUI. Related risk factors are a short vaginal length (&le;6 cm) and a wide vaginal introitus (over 4 fingerbreadths). Prolapse severity and sexual activity are not risk factors for failure to fit a pessary. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Risk factors for an inability to fit a pessary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After a successful pessary fitting trial for prolapse, short-term (two to six months) satisfaction and continued use is approximately 80 percent, and medium-term (one to two years) satisfaction and continued use is approximately 60 percent. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Treatment of prolapse trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 80 percent of prolapse symptoms resolve (bulge, pressure, splinting), 50 percent of urinary symptoms resolve (stress and urge incontinence and voiding difficulty), 40 percent of bowel symptoms resolve (anal incontinence, anal urgency, and obstructive symptoms), and 50 percent report increased sexual frequency and satisfaction. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Treatment of prolapse trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anatomically, the genital hiatus will decrease in size. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Treatment of prolapse trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for discontinued pessary use are severe posterior vaginal prolapse, the development of occult SUI, and desire for surgery. Prolapse severity and desire for sexual activity are not risk factors for discontinued pessary use. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Risk factors for discontinuing pessary use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with urinary incontinence, short-term (three-month) efficacy is approximately 50 percent. Twelve-month satisfaction is approximately 50 percent. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Treatment of urinary incontinence trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with SUI who desire nonsurgical therapy, we suggest pelvic floor muscle training over use of a continence pessary (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Treatment of urinary incontinence trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pessaries have been used in women with POP to diagnose occult SUI and to predict postoperative cure of urinary retention after prolapse surgery. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'For prediction of surgical outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major complications are rare. Side effects include vaginal erosions, vaginal bleeding, and vaginal discharge. They usually occur in the setting of vaginal atrophy, and low-dose estrogen vaginal cream can treat or prevent these symptoms. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Management of side effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21292280\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The opinions or assertions contained herein are the private views of the author and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/1\">",
"      Swift S, Woodman P, O'Boyle A, et al. Pelvic Organ Support Study (POSST): the distribution, clinical definition, and epidemiologic condition of pelvic organ support defects. Am J Obstet Gynecol 2005; 192:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/2\">",
"      Nygaard I, Bradley C, Brandt D, Women's Health Initiative. Pelvic organ prolapse in older women: prevalence and risk factors. Obstet Gynecol 2004; 104:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/3\">",
"      Samuelsson EC, Victor FT, Tibblin G, Sv&auml;rdsudd KF. Signs of genital prolapse in a Swedish population of women 20 to 59 years of age and possible related factors. Am J Obstet Gynecol 1999; 180:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/4\">",
"      Grodstein F, Fretts R, Lifford K, et al. Association of age, race, and obstetric history with urinary symptoms among women in the Nurses' Health Study. Am J Obstet Gynecol 2003; 189:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/5\">",
"      Melville JL, Katon W, Delaney K, Newton K. Urinary incontinence in US women: a population-based study. Arch Intern Med 2005; 165:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/6\">",
"      Thom DH, van den Eeden SK, Ragins AI, et al. Differences in prevalence of urinary incontinence by race/ethnicity. J Urol 2006; 175:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/7\">",
"      Boyles SH, Weber AM, Meyn L. Procedures for pelvic organ prolapse in the United States, 1979-1997. Am J Obstet Gynecol 2003; 188:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/8\">",
"      Waetjen LE, Subak LL, Shen H, et al. Stress urinary incontinence surgery in the United States. Obstet Gynecol 2003; 101:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/9\">",
"      Olsen AL, Smith VJ, Bergstrom JO, et al. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997; 89:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/10\">",
"      Clemons JL, Aguilar VC, Tillinghast TA, et al. Risk factors associated with an unsuccessful pessary fitting trial in women with pelvic organ prolapse. Am J Obstet Gynecol 2004; 190:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/11\">",
"      Donnelly MJ, Powell-Morgan S, Olsen AL, Nygaard IE. Vaginal pessaries for the management of stress and mixed urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2004; 15:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/12\">",
"      Powers K, Lazarou G, Wang A, et al. Pessary use in advanced pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/13\">",
"      Kapoor DS, Thakar R, Sultan AH, Oliver R. Conservative versus surgical management of prolapse: what dictates patient choice? Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/14\">",
"      Heit M, Rosenquist C, Culligan P, et al. Predicting treatment choice for patients with pelvic organ prolapse. Obstet Gynecol 2003; 101:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/15\">",
"      Pott-Grinstein E, Newcomer JR. Gynecologists' patterns of prescribing pessaries. J Reprod Med 2001; 46:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/16\">",
"      Cundiff GW, Weidner AC, Visco AG, et al. A survey of pessary use by members of the American urogynecologic society. Obstet Gynecol 2000; 95:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/17\">",
"      Cundiff GW, Amundsen CL, Bent AE, et al. The PESSRI study: symptom relief outcomes of a randomized crossover trial of the ring and Gellhorn pessaries. Am J Obstet Gynecol 2007; 196:405.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/18\">",
"      Myers DL, LaSala CA, Murphy JA. Double pessary use in grade 4 uterine and vaginal prolapse. Obstet Gynecol 1998; 91:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/19\">",
"      Singh K, Reid WM. Non-surgical treatment of uterovaginal prolapse using double vaginal rings. BJOG 2001; 108:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/20\">",
"      Allen WA, Leek H, Izurieta A, Moore KH. Update: the \"Contiform\" intravaginal device in four sizes for the treatment of stress incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/21\">",
"      Ziv E, Stanton SL, Abarbanel J. Efficacy and safety of a novel disposable intravaginal device for treating stress urinary incontinence. Am J Obstet Gynecol 2008; 198:594.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/22\">",
"      Bump RC, Mattiasson A, B&oslash; K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 1996; 175:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/23\">",
"      Gorti M, Hudelist G, Simons A. Evaluation of vaginal pessary management: a UK-based survey. J Obstet Gynaecol 2009; 29:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/24\">",
"      Hanson LA, Schulz JA, Flood CG, et al. Vaginal pessaries in managing women with pelvic organ prolapse and urinary incontinence: patient characteristics and factors contributing to success. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/25\">",
"      Wu V, Farrell SA, Baskett TF, Flowerdew G. A simplified protocol for pessary management. Obstet Gynecol 1997; 90:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/26\">",
"      Nguyen JN, Jones CR. Pessary treatment of pelvic relaxation: factors affecting successful fitting and continued use. J Wound Ostomy Continence Nurs 2005; 32:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/27\">",
"      Alnaif B, Drutz HP. Bacterial vaginosis increases in pessary users. Int Urogynecol J Pelvic Floor Dysfunct 2000; 11:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/28\">",
"      Moore KH, Foote A, Burton G, King J. An open study of the bladder neck support prosthesis in genuine stress incontinence. Br J Obstet Gynaecol 1999; 106:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/29\">",
"      Farrell SA, Baydock S, Amir B, Fanning C. Effectiveness of a new self-positioning pessary for the management of urinary incontinence in women. Am J Obstet Gynecol 2007; 196:474.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/30\">",
"      Robert M, Mainprize TC. Long-term assessment of the incontinence ring pessary for the treatment of stress incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2002; 13:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/31\">",
"      Fernando RJ, Thakar R, Sultan AH, et al. Effect of vaginal pessaries on symptoms associated with pelvic organ prolapse. Obstet Gynecol 2006; 108:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/32\">",
"      Lukban JC, Aguirre OA, Davila GW, Sand PK. Safety and effectiveness of Colpexin Sphere in the treatment of pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/33\">",
"      Nager CW, Richter HE, Nygaard I, et al. Incontinence pessaries: size, POPQ measures, and successful fitting. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/34\">",
"      Mutone MF, Terry C, Hale DS, Benson JT. Factors which influence the short-term success of pessary management of pelvic organ prolapse. Am J Obstet Gynecol 2005; 193:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/35\">",
"      Maito JM, Quam ZA, Craig E, et al. Predictors of successful pessary fitting and continued use in a nurse-midwifery pessary clinic. J Midwifery Womens Health 2006; 51:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/36\">",
"      Brincat C, Kenton K, Pat Fitzgerald M, Brubaker L. Sexual activity predicts continued pessary use. Am J Obstet Gynecol 2004; 191:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/37\">",
"      Handa VL, Jones M. Do pessaries prevent the progression of pelvic organ prolapse? Int Urogynecol J Pelvic Floor Dysfunct 2002; 13:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/38\">",
"      Sulak PJ, Kuehl TJ, Shull BL. Vaginal pessaries and their use in pelvic relaxation. J Reprod Med 1993; 38:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/39\">",
"      Farrell SA, Singh B, Aldakhil L. Continence pessaries in the management of urinary incontinence in women. J Obstet Gynaecol Can 2004; 26:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/40\">",
"      Mokrzycki ML, Hatangadi SB, Zaccardi JE, Cox S. Preexisting stress urinary incontinence: a predictor of discontinuation with pessary management. J Low Genit Tract Dis 2001; 5:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/41\">",
"      Friedman S, Sandhu KS, Wang C, et al. Factors influencing long-term pessary use. Int Urogynecol J 2010; 21:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/42\">",
"      Clemons JL, Aguilar VC, Tillinghast TA, et al. Patient satisfaction and changes in prolapse and urinary symptoms in women who were fitted successfully with a pessary for pelvic organ prolapse. Am J Obstet Gynecol 2004; 190:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/43\">",
"      Clemons JL, Aguilar VC, Sokol ER, et al. Patient characteristics that are associated with continued pessary use versus surgery after 1 year. Am J Obstet Gynecol 2004; 191:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/44\">",
"      Patel M, Mellen C, O'Sullivan DM, LaSala CA. Impact of pessary use on prolapse symptoms, quality of life, and body image. Am J Obstet Gynecol 2010; 202:499.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/45\">",
"      Sarma S, Ying T, Moore KH. Long-term vaginal ring pessary use: discontinuation rates and adverse events. BJOG 2009; 116:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/46\">",
"      Lone F, Thakar R, Sultan AH, Karamalis G. A 5-year prospective study of vaginal pessary use for pelvic organ prolapse. Int J Gynaecol Obstet 2011; 114:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/47\">",
"      Lowenstein L, Gamble T, Sanses TV, et al. Changes in sexual function after treatment for prolapse are related to the improvement in body image perception. J Sex Med 2010; 7:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/48\">",
"      Barber MD, Walters MD, Cundiff GW, PESSRI Trial Group. Responsiveness of the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ) in women undergoing vaginal surgery and pessary treatment for pelvic organ prolapse. Am J Obstet Gynecol 2006; 194:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/49\">",
"      Komesu YM, Rogers RG, Rode MA, et al. Pelvic floor symptom changes in pessary users. Am J Obstet Gynecol 2007; 197:620.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/50\">",
"      Abdool Z, Thakar R, Sultan AH, Oliver RS. Prospective evaluation of outcome of vaginal pessaries versus surgery in women with symptomatic pelvic organ prolapse. Int Urogynecol J 2011; 22:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/51\">",
"      Jones K, Yang L, Lowder JL, et al. Effect of pessary use on genital hiatus measurements in women with pelvic organ prolapse. Obstet Gynecol 2008; 112:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/52\">",
"      Komesu YM, Rogers RG, Rode MA, et al. Patient-selected goal attainment for pessary wearers: what is the clinical relevance? Am J Obstet Gynecol 2008; 198:577.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/53\">",
"      Bhatia NN, Bergman A, Gunning JE. Urodynamic effects of a vaginal pessary in women with stress urinary incontinence. Am J Obstet Gynecol 1983; 147:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/54\">",
"      Noblett KL, McKinney A, Lane FL. Effects of the incontinence dish pessary on urethral support and urodynamic parameters. Am J Obstet Gynecol 2008; 198:592.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/55\">",
"      Komesu YM, Ketai LH, Rogers RG, et al. Restoration of continence by pessaries: magnetic resonance imaging assessment of mechanism of action. Am J Obstet Gynecol 2008; 198:563.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/56\">",
"      Rosenzweig, BA. Severe genital prolapse and its relationship to detrusor instability. Int Urogynecol J 1995; 6:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/57\">",
"      Richter HE, Burgio KL, Brubaker L, et al. Continence pessary compared with behavioral therapy or combined therapy for stress incontinence: a randomized controlled trial. Obstet Gynecol 2010; 115:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/58\">",
"      Handa VL, Whitcomb E, Weidner AC, et al. Sexual function before and after non-surgical treatment for stress urinary incontinence. Female Pelvic Med Reconstr Surg 2011; 17:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/59\">",
"      Nygaard I. Prevention of exercise incontinence with mechanical devices. J Reprod Med 1995; 40:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/60\">",
"      Abu-Sitta, MI, Kapur, G, Enhorning, G. Stress incontinence alleviated by an intravaginal device. Int Urogynecol J 1995; 6:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/61\">",
"      Davila GW, Neal D, Horbach N, et al. A bladder-neck support prosthesis for women with stress and mixed incontinence. Obstet Gynecol 1999; 93:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/62\">",
"      Vierhout ME, Lose G. Preventive vaginal and intra-urethral devices in the treatment of female urinary stress incontinence. Curr Opin Obstet Gynecol 1997; 9:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/63\">",
"      Bergman A, Koonings PP, Ballard CA. Predicting postoperative urinary incontinence development in women undergoing operation for genitourinary prolapse. Am J Obstet Gynecol 1988; 158:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/64\">",
"      Chaikin DC, Groutz A, Blaivas JG. Predicting the need for anti-incontinence surgery in continent women undergoing repair of severe urogenital prolapse. J Urol 2000; 163:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/65\">",
"      Hextall A, Boos K, Cardozo L, et al. Videocystourethrography with a ring pessary in situ. A clinically useful preoperative investigation for continent women with urogenital prolapse? Int Urogynecol J Pelvic Floor Dysfunct 1998; 9:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/66\">",
"      Liang CC, Chang YL, Chang SD, et al. Pessary test to predict postoperative urinary incontinence in women undergoing hysterectomy for prolapse. Obstet Gynecol 2004; 104:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/67\">",
"      Liapis A, Bakas P, Georgantopoulou C, Creatsas G. The use of the pessary test in preoperative assessment of women with severe genital prolapse. Eur J Obstet Gynecol Reprod Biol 2011; 155:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/68\">",
"      Reena C, Kekre AN, Kekre N. Occult stress incontinence in women with pelvic organ prolapse. Int J Gynaecol Obstet 2007; 97:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/69\">",
"      Brubaker L, Cundiff GW, Fine P, et al. Abdominal sacrocolpopexy with Burch colposuspension to reduce urinary stress incontinence. N Engl J Med 2006; 354:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/70\">",
"      Lazarou G, Scotti RJ, Mikhail MS, et al. Pessary reduction and postoperative cure of retention in women with anterior vaginal wall prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2004; 15:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/71\">",
"      Romanzi LJ, Chaikin DC, Blaivas JG. The effect of genital prolapse on voiding. J Urol 1999; 161:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/72\">",
"      Goldstein I, Wise GJ, Tancer ML. A vesicovaginal fistula and intravesical foreign body. A rare case of the neglected pessary. Am J Obstet Gynecol 1990; 163:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/73\">",
"      Duncan LE, Foltzer M, O'Hearn M. Unilateral hydronephrosis, pyelonephritis, and bacteremia caused by a neglected vaginal ring pessary. J Am Geriatr Soc 1997; 45:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/74\">",
"      Roberge RJ, Keller C, Garfinkel M. Vaginal pessary-induced mechanical bowel obstruction. J Emerg Med 2001; 20:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/75\">",
"      Hanavadi S, Durham-Hall A, Oke T, Aston N. Forgotten vaginal pessary eroding into rectum. Ann R Coll Surg Engl 2004; 86:W18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/76\">",
"      Arias BE, Ridgeway B, Barber MD. Complications of neglected vaginal pessaries: case presentation and literature review. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/77\">",
"      Kaaki B, Mahajan ST. Vesicovaginal fistula resulting from a well-cared-for pessary. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/7/17530/abstract/78\">",
"      Jain A, Majoko F, Freites O. How innocent is the vaginal pessary? Two cases of vaginal cancer associated with pessary use. J Obstet Gynaecol 2006; 26:829.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8081 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-791DB7C3D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17530=[""].join("\n");
var outline_f17_7_17530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATIENT ACCEPTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TYPES OF PESSARIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Support versus space filling pessaries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Support pessaries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Ring pessaries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lever pessaries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Gehrung pessary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Shaatz pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Space-filling pessaries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Gellhorn pessary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Donut pessary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cube pessary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Inflatable pessary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Spherical pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Incontinence pessaries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Incontinence ring and dish",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Bell-shaped incontinence pessary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Cylindrical intravaginal device",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Continence Ring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Disposable intravaginal device",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PESSARY FITTING TRIAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Fitting the pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Management of side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Duration of use and replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Pessary fitting trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Risk factors for an inability to fit a pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Treatment of prolapse trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Risk factors for discontinuing pessary use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Treatment of urinary incontinence trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      For prediction of surgical outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21292280\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/8081\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8081|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/20/24897\" title=\"figure 1\">",
"      Insertion of ring pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/61/4048\" title=\"figure 2\">",
"      Ring pessary in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/34/32289\" title=\"figure 3\">",
"      Milex incontinence ring pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/7/36977\" title=\"figure 4\">",
"      Insertion of lever pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/13/42207\" title=\"figure 5\">",
"      Gellhorn pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/10/31919\" title=\"figure 6\">",
"      Insertion of donut pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/23/41330\" title=\"figure 7\">",
"      Insertion of cube pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/22/20833\" title=\"figure 8\">",
"      Insertion inflatoball pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/2/1056\" title=\"figure 9\">",
"      Colpexin sphere pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/48/39681\" title=\"figure 10\">",
"      Estimating pessary size",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8081|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/33/26128\" title=\"picture 1\">",
"      Types of pessaries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/26/36271\" title=\"picture 2\">",
"      Gelhorn pessaries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/10/38051\" title=\"picture 3\">",
"      Fenestrated cube pessary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=related_link\">",
"      An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/62/44001?source=related_link\">",
"      Patient information: Pelvic organ prolapse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/16/9474?source=related_link\">",
"      Patient information: Urinary incontinence in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=related_link\">",
"      Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=related_link\">",
"      Pelvic organ prolapse in women: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=related_link\">",
"      Stress urinary incontinence in women: Choosing a primary surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_7_17531="Characteristics of carcinoids";
var content_f17_7_17531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of carcinoid tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"26%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Foregut",
"       </td>",
"       <td class=\"subtitle1\">",
"        Midgut",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hindgut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Localization",
"        </strong>",
"       </td>",
"       <td>",
"        Stomach, duodenum, bronchus, thymus",
"       </td>",
"       <td>",
"        Jejunum, ileum, appendix, ascending colon",
"       </td>",
"       <td>",
"        Transverse, descending, and sigmoid colon, rectum, genitourinary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Secretory products",
"        </strong>",
"       </td>",
"       <td>",
"        5-hydroxytryptophan, histamine, multiple polypeptides",
"       </td>",
"       <td>",
"        Serotonin prostaglandins, polypeptides",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Carcinoid syndrome",
"        </strong>",
"       </td>",
"       <td>",
"        Rare, and atypical when it happens",
"       </td>",
"       <td>",
"        Classic",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17531=[""].join("\n");
var outline_f17_7_17531=null;
var title_f17_7_17532="Burn depth";
var content_f17_7_17532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Burn depth",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Depth",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cause",
"      </td>",
"      <td class=\"subtitle1\">",
"       Appearance",
"      </td>",
"      <td class=\"subtitle1\">",
"       Sensation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Healing time",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Superficial",
"      </td>",
"      <td>",
"       <p>",
"        Ultraviolet exposure",
"       </p>",
"       <p>",
"        Very short flash",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Dry, red",
"       </p>",
"       <p>",
"        Blanches with pressure",
"       </p>",
"      </td>",
"      <td>",
"       Painful",
"      </td>",
"      <td>",
"       3 to 6 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Superficial partial-thickness",
"      </td>",
"      <td>",
"       <p>",
"        Scald (spill or splash)",
"       </p>",
"       <p>",
"        Short flash",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Blisters",
"       </p>",
"       <p>",
"        Moist, red, weeping",
"       </p>",
"       <p>",
"        Blanches with pressure",
"       </p>",
"      </td>",
"      <td>",
"       Painful to temperature and air",
"      </td>",
"      <td>",
"       7 to 20 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Deep partial-thickness",
"      </td>",
"      <td>",
"       <p>",
"        Scald (spill)",
"       </p>",
"       <p>",
"        Flame",
"       </p>",
"       <p>",
"        Oil",
"       </p>",
"       <p>",
"        Grease",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Blisters (easily unroofed)",
"       </p>",
"       <p>",
"        Wet or waxy dry",
"       </p>",
"       <p>",
"        Variable color (patchy to cheesy white to red)",
"       </p>",
"       <p>",
"        Does not blanch with pressure",
"       </p>",
"      </td>",
"      <td>",
"       Perceptive of pressure only",
"      </td>",
"      <td>",
"       &gt;21 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Full-thickness",
"      </td>",
"      <td>",
"       <p>",
"        Scald (immersion)",
"       </p>",
"       <p>",
"        Flame",
"       </p>",
"       <p>",
"        Steam",
"       </p>",
"       <p>",
"        Oil",
"       </p>",
"       <p>",
"        Grease",
"       </p>",
"       <p>",
"        Chemical",
"       </p>",
"       <p>",
"        Electrical",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Waxy white to leathery gray to charred and black",
"       </p>",
"       <p>",
"        Dry and inelastic",
"       </p>",
"       <p>",
"        No blanching with pressure",
"       </p>",
"      </td>",
"      <td>",
"       Deep pressure only",
"      </td>",
"      <td>",
"       Never (if &gt;2 percent total body surface area)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Mertens, DM, Jenkins, ME, Warden, GD, Med Clin North Am 1997; 32:343; and Peate, WF, Am Fam Physician 1992; 45:1321; and Clayton, MC, Solem, LD, Postgrad Med 1995; 97:151.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17532=[""].join("\n");
var outline_f17_7_17532=null;
var title_f17_7_17533="Central sleep apnea";
var content_f17_7_17533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Central sleep apnea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 227px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is no respiratory effort, as shown by absence of changes in esophageal pressure (Pes), at the time of cessation of airflow. The arrow illustrates that arousal in central apnea typically occurs in the middle of the hyperpneic phase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17533=[""].join("\n");
var outline_f17_7_17533=null;
var title_f17_7_17534="History in wheeze I";
var content_f17_7_17534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51034%7EPULM%2F64862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51034%7EPULM%2F64862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of wheezing due to upper airway diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Postnasal drip syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of postnasal drip, throat clearing, nasal discharge; physical examination shows oropharyngeal secretions or cobblestone appearance.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Supraglottitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of sore throat out of proportion to pharyngitis; evidence of supraglottitis on endoscopy or lateral neck roentgenograms.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Paradoxical vocal cord motion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       Lack of symptomatic response to bronchodilators, presence of stridor plus wheeze in absence of increased P(A-a)02; extrathoracic, variable obstruction on flow-volume loops; paradoxical inspiratory and/or early expiratory adduction of vocal cords on laryngoscopy during wheezing. This syndrome can masquerade as asthma, can be provoked by exercise, often coexists with asthma, and may be secondary to gastroesophageal reflux disease.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Retropharyngeal abscess",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of stiff neck, sore throat, fever, trauma to posterior pharynx; swelling noted by lateral neck or CT roentgenograms.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Laryngotracheal injury due to tracheal cannulation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of cannulation of trachea by endotracheal or tracheostomy tube; evidence of intra or extrathoracic, variable obstruction on F-V loops, neck/chest roentgenograms, laryngoscopy or bronchoscopy, or all of these. Flow-volume loops with helium and air may reveal large airway obstruction superimposed on underlying small airway disease (eg, COPD).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Neoplasms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       Carcinoid tumor is suspected when there is hemoptysis, unilateral wheeze, or evidence of lobar collapse on chest roentgenogram; bronchogenic carcinoma considered in the same setting in a cigarette smoker; diagnosis is confirmed by bronchoscopy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Anaphylaxis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       Abrupt onset of wheezing with urticaria, angioedema, nausea, diarrhea, and hypotension, especially following insect bite or administration of drug or intravenous contrast; family history. When symptoms occur during or immediately after exercise, consider the diagnosis of exercise-induced anaphylaxis; or food dependent exercise-induced anaphylaxis when symptoms occur after eating (especially wheat) followed by exercise.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of wheezing due to lower airway diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Aspiration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of risk for pharyngeal dysfunction or gastroesophageal reflux disease.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Modified barium swallow, 24 hour esophageal pH monitoring, gastroesophagoscopy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Bronchiectasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of episodes of productive cough, fever, or recurrent pneumonias.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Suggestive chest radiograph or typical high resolution chest CT findings; allergic bronchopulmonary aspergillosis should be considered when bronchiectasis is central.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Bronchiolitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of respiratory infection, connective tissue disease, transplantation, ulcerative colitis, development of chronic airflow obstruction over months to few years rather than over many years in a non-smoker.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Mixed obstructive and restrictive pattern on pulmonary function tests and hyperinflation and fine nodular infiltrates on chest radiograph, or suggestive chest CT findings.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Carcinoid syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of episodes of flushing and watery diarrhea.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Elevated 5-hydroxyindoleacetic acid level in a 24 hour urine specimen.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       COPD",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of dyspnea on exertion and productive cough in cigarette smoker; or patient exposed to another environmental irritant; since productive cough is non-specific, it should only be ascribed to COPD when other cough-phlegm syndromes have been excluded forced expiratory time &gt;4 sec, decreased breath-sound intensity, and unforced wheezing during auscultation.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Irreversible, or only partially reversible, expiratory airflow obstruction on spirometry; chest radiograph may show hyperinflation, bullae.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Cystic fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       Combination of productive cough, digital clubbing, bronchiectasis, progressive chronic obstructive lung disease with Pseudomonas colonization/infection, obstructive azoospermia, family history, pancreatic insufficiency.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Two sweat chloride determinations &gt;60 meq/L; some patients are not diagnosed until adulthood, in one instance as late as age 69; when sweat test is occasionally normal, definitive diagnosis may require nasal transepithelial voltage measurements and genotyping.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Heart failure (cardiac asthma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History and physical consistent with passive congestion of the lungs, impaired lung lymphatic drainage; crackles in addition to wheeze.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Elevated brain natriuretic peptide; abnormal chest radiograph, echocardiogram, radionuclide ventriculography, cardiac catheterization, or combinations of these.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Lymphangitic carcinomatosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of dyspnea or prior malignancy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Reticulonodular infiltrates with or without pleural effusions; suggestive high resolution chest CT scan; bronchoscopy with transbronchial biopsies may be diagnostic.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Noncardiogenic pulmonary edema",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       Acute onset of dyspnea in setting of risk factors for ARDS; chest imaging shows interstitial/alveolar opacities; substantial gas transfer defect.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Parasitic infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       Consider in a non-asthmatic who has traveled to an endemic area and complains of fatigue, weight loss, fever.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       Peripheral blood eosinophilia; infiltrates on chest radiograph; stools for ova and parasites for non-filarial causes; blood serologic studies for filaria/strongyloides.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pulmonary embolism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of risk factors for thromboembolic disease. Wheezing is rarely heard in venous thromboembolism.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Testing:",
"       </strong>",
"       CT pulmonary angiogram.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17534=[""].join("\n");
var outline_f17_7_17534=null;
var title_f17_7_17535="VCUG Grade V reflux";
var content_f17_7_17535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Voiding cystourethrogram (VCUG) demonstrating unilateral Grade V vesicoureteral reflux",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_7_17535=[""].join("\n");
var outline_f17_7_17535=null;
